JP2014518234A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014518234A5 JP2014518234A5 JP2014517667A JP2014517667A JP2014518234A5 JP 2014518234 A5 JP2014518234 A5 JP 2014518234A5 JP 2014517667 A JP2014517667 A JP 2014517667A JP 2014517667 A JP2014517667 A JP 2014517667A JP 2014518234 A5 JP2014518234 A5 JP 2014518234A5
- Authority
- JP
- Japan
- Prior art keywords
- methyl
- triazolo
- quinoxaline
- chlorophenyl
- quinoxalin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 33
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 12
- -1 pyridin-4-yloxy Chemical group 0.000 description 5
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 description 3
- 125000004182 2-chlorophenyl group Chemical group [H]C1=C([H])C(Cl)=C(*)C([H])=C1[H] 0.000 description 2
- RBQZSOSIDAYTQQ-UHFFFAOYSA-N 4-[[1-[5-(2-methoxyethyl)pyridin-3-yl]-4-methyl-[1,2,4]triazolo[4,3-a]quinoxalin-8-yl]methyl]morpholine Chemical compound COCCC1=CN=CC(C=2N3C4=CC(CN5CCOCC5)=CC=C4N=C(C)C3=NN=2)=C1 RBQZSOSIDAYTQQ-UHFFFAOYSA-N 0.000 description 2
- 150000001412 amines Chemical class 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- XSCHRSMBECNVNS-UHFFFAOYSA-N quinoxaline Chemical compound N1=CC=NC2=CC=CC=C21 XSCHRSMBECNVNS-UHFFFAOYSA-N 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- RFZHZDSZQMLWPM-UHFFFAOYSA-N (4-methyl-1-phenyl-[1,2,4]triazolo[4,3-a]quinoxalin-8-yl)methanol Chemical compound N=1N=C2C(C)=NC3=CC=C(CO)C=C3N2C=1C1=CC=CC=C1 RFZHZDSZQMLWPM-UHFFFAOYSA-N 0.000 description 1
- PBXNICUZJRRAJG-UHFFFAOYSA-N 1-(2,4-dichlorophenyl)-4-methyl-n-(pyridin-2-ylmethyl)-[1,2,4]triazolo[4,3-a]quinoxaline-8-carboxamide Chemical compound N=1N=C2C(C)=NC3=CC=C(C(=O)NCC=4N=CC=CC=4)C=C3N2C=1C1=CC=C(Cl)C=C1Cl PBXNICUZJRRAJG-UHFFFAOYSA-N 0.000 description 1
- UFSFBTVVLZCSCY-UHFFFAOYSA-N 1-(2,5-dichlorophenyl)-4-methyl-n-(pyridin-2-ylmethyl)-[1,2,4]triazolo[4,3-a]quinoxaline-8-carboxamide Chemical compound N=1N=C2C(C)=NC3=CC=C(C(=O)NCC=4N=CC=CC=4)C=C3N2C=1C1=CC(Cl)=CC=C1Cl UFSFBTVVLZCSCY-UHFFFAOYSA-N 0.000 description 1
- URLXPSUXGAGTAF-UHFFFAOYSA-N 1-(2,6-dichlorophenyl)-n-ethyl-4-methyl-[1,2,4]triazolo[4,3-a]quinoxaline-8-carboxamide Chemical compound N12C3=CC(C(=O)NCC)=CC=C3N=C(C)C2=NN=C1C1=C(Cl)C=CC=C1Cl URLXPSUXGAGTAF-UHFFFAOYSA-N 0.000 description 1
- DOKQEIRHEFIUMS-UHFFFAOYSA-N 1-(2-chloro-4-methoxyphenyl)-4-methyl-n-(pyridin-2-ylmethyl)-[1,2,4]triazolo[4,3-a]quinoxaline-8-carboxamide Chemical compound ClC1=CC(OC)=CC=C1C1=NN=C2N1C1=CC(C(=O)NCC=3N=CC=CC=3)=CC=C1N=C2C DOKQEIRHEFIUMS-UHFFFAOYSA-N 0.000 description 1
- ADXGWVHEMCWLBI-UHFFFAOYSA-N 1-(2-chloro-5-ethoxyphenyl)-4-methyl-8-(2-pyridin-3-ylethoxy)-[1,2,4]triazolo[4,3-a]quinoxaline Chemical compound CCOC1=CC=C(Cl)C(C=2N3C4=CC(OCCC=5C=NC=CC=5)=CC=C4N=C(C)C3=NN=2)=C1 ADXGWVHEMCWLBI-UHFFFAOYSA-N 0.000 description 1
- RHGSISTUFNGCAI-UHFFFAOYSA-N 1-(2-chloro-5-ethoxyphenyl)-4-methyl-8-(4-methylpiperazin-1-yl)-[1,2,4]triazolo[4,3-a]quinoxaline Chemical compound CCOC1=CC=C(Cl)C(C=2N3C4=CC(=CC=C4N=C(C)C3=NN=2)N2CCN(C)CC2)=C1 RHGSISTUFNGCAI-UHFFFAOYSA-N 0.000 description 1
- QPXNLQLXPDJMAK-UHFFFAOYSA-N 1-(2-chloro-5-ethoxyphenyl)-4-methyl-8-[(4-methylpiperazin-1-yl)methyl]-[1,2,4]triazolo[4,3-a]quinoxaline Chemical compound CCOC1=CC=C(Cl)C(C=2N3C4=CC(CN5CCN(C)CC5)=CC=C4N=C(C)C3=NN=2)=C1 QPXNLQLXPDJMAK-UHFFFAOYSA-N 0.000 description 1
- ICFQVFGTONAAIZ-UHFFFAOYSA-N 1-(2-chloro-5-ethoxyphenyl)-8-[(4-fluoropiperidin-1-yl)methyl]-4-methyl-[1,2,4]triazolo[4,3-a]quinoxaline Chemical compound CCOC1=CC=C(Cl)C(C=2N3C4=CC(CN5CCC(F)CC5)=CC=C4N=C(C)C3=NN=2)=C1 ICFQVFGTONAAIZ-UHFFFAOYSA-N 0.000 description 1
- RXSACHXZPRTNLY-UHFFFAOYSA-N 1-(2-chloro-5-fluorophenyl)-4-methyl-n-(pyridin-2-ylmethyl)-[1,2,4]triazolo[4,3-a]quinoxaline-8-carboxamide Chemical compound N=1N=C2C(C)=NC3=CC=C(C(=O)NCC=4N=CC=CC=4)C=C3N2C=1C1=CC(F)=CC=C1Cl RXSACHXZPRTNLY-UHFFFAOYSA-N 0.000 description 1
- KSVZPHFVGCYJBQ-UHFFFAOYSA-N 1-(2-chloro-5-methoxyphenyl)-4-methyl-n-(pyridin-2-ylmethyl)-[1,2,4]triazolo[4,3-a]quinoxaline-8-carboxamide Chemical compound COC1=CC=C(Cl)C(C=2N3C4=CC(=CC=C4N=C(C)C3=NN=2)C(=O)NCC=2N=CC=CC=2)=C1 KSVZPHFVGCYJBQ-UHFFFAOYSA-N 0.000 description 1
- RFPHPZFQKKOGCW-UHFFFAOYSA-N 1-(2-chloro-5-methoxyphenyl)-8-[(4-fluoropiperidin-1-yl)methyl]-4-methyl-[1,2,4]triazolo[4,3-a]quinoxaline Chemical compound COC1=CC=C(Cl)C(C=2N3C4=CC(CN5CCC(F)CC5)=CC=C4N=C(C)C3=NN=2)=C1 RFPHPZFQKKOGCW-UHFFFAOYSA-N 0.000 description 1
- IZFCCDRZSRDTDB-UHFFFAOYSA-N 1-(2-chloro-5-methylphenyl)-4-methyl-n-(pyridin-2-ylmethyl)-[1,2,4]triazolo[4,3-a]quinoxaline-8-carboxamide Chemical compound CC1=CC=C(Cl)C(C=2N3C4=CC(=CC=C4N=C(C)C3=NN=2)C(=O)NCC=2N=CC=CC=2)=C1 IZFCCDRZSRDTDB-UHFFFAOYSA-N 0.000 description 1
- DXMWTQIHTKNDCL-UHFFFAOYSA-N 1-(2-chloro-5-propan-2-yloxyphenyl)-4-methyl-8-(4-methylpiperazin-1-yl)-[1,2,4]triazolo[4,3-a]quinoxaline Chemical compound CC(C)OC1=CC=C(Cl)C(C=2N3C4=CC(=CC=C4N=C(C)C3=NN=2)N2CCN(C)CC2)=C1 DXMWTQIHTKNDCL-UHFFFAOYSA-N 0.000 description 1
- DXRORSSYLRSSCH-UHFFFAOYSA-N 1-(2-chloro-5-propan-2-yloxyphenyl)-4-methyl-8-[(4-methylpiperazin-1-yl)methyl]-[1,2,4]triazolo[4,3-a]quinoxaline Chemical compound CC(C)OC1=CC=C(Cl)C(C=2N3C4=CC(CN5CCN(C)CC5)=CC=C4N=C(C)C3=NN=2)=C1 DXRORSSYLRSSCH-UHFFFAOYSA-N 0.000 description 1
- SQCWLPYHEITKLZ-UHFFFAOYSA-N 1-(2-chloro-5-propan-2-yloxyphenyl)-8-[(4-fluoropiperidin-1-yl)methyl]-4-methyl-[1,2,4]triazolo[4,3-a]quinoxaline Chemical compound CC(C)OC1=CC=C(Cl)C(C=2N3C4=CC(CN5CCC(F)CC5)=CC=C4N=C(C)C3=NN=2)=C1 SQCWLPYHEITKLZ-UHFFFAOYSA-N 0.000 description 1
- KSLZFRSYFBPHNT-UHFFFAOYSA-N 1-(2-chloro-5-propoxyphenyl)-4-methyl-8-(2-pyridin-3-ylethoxy)-[1,2,4]triazolo[4,3-a]quinoxaline Chemical compound CCCOC1=CC=C(Cl)C(C=2N3C4=CC(OCCC=5C=NC=CC=5)=CC=C4N=C(C)C3=NN=2)=C1 KSLZFRSYFBPHNT-UHFFFAOYSA-N 0.000 description 1
- AJLATRGQTGOZDX-UHFFFAOYSA-N 1-(2-chloro-5-propoxyphenyl)-4-methyl-8-(4-methylpiperazin-1-yl)-[1,2,4]triazolo[4,3-a]quinoxaline Chemical compound CCCOC1=CC=C(Cl)C(C=2N3C4=CC(=CC=C4N=C(C)C3=NN=2)N2CCN(C)CC2)=C1 AJLATRGQTGOZDX-UHFFFAOYSA-N 0.000 description 1
- MWJHRMBPKCJYLL-UHFFFAOYSA-N 1-(2-chloro-5-propoxyphenyl)-4-methyl-8-[(4-methylpiperazin-1-yl)methyl]-[1,2,4]triazolo[4,3-a]quinoxaline Chemical compound CCCOC1=CC=C(Cl)C(C=2N3C4=CC(CN5CCN(C)CC5)=CC=C4N=C(C)C3=NN=2)=C1 MWJHRMBPKCJYLL-UHFFFAOYSA-N 0.000 description 1
- ROZSPBVQXAQIAI-INIZCTEOSA-N 1-(2-chloro-5-propoxyphenyl)-4-methyl-8-[[(2s)-pyrrolidin-2-yl]methoxy]-[1,2,4]triazolo[4,3-a]quinoxaline Chemical compound CCCOC1=CC=C(Cl)C(C=2N3C4=CC(OC[C@H]5NCCC5)=CC=C4N=C(C)C3=NN=2)=C1 ROZSPBVQXAQIAI-INIZCTEOSA-N 0.000 description 1
- YRVJDPUKLYCAAV-UHFFFAOYSA-N 1-(2-chloro-5-propoxyphenyl)-8-[(4-fluoropiperidin-1-yl)methyl]-4-methyl-[1,2,4]triazolo[4,3-a]quinoxaline Chemical compound CCCOC1=CC=C(Cl)C(C=2N3C4=CC(CN5CCC(F)CC5)=CC=C4N=C(C)C3=NN=2)=C1 YRVJDPUKLYCAAV-UHFFFAOYSA-N 0.000 description 1
- ADCUCKZPYWAEBQ-UHFFFAOYSA-N 1-(2-chloro-6-fluorophenyl)-8-ethenyl-4-methyl-[1,2,4]triazolo[4,3-a]quinoxaline Chemical compound N=1N=C2C(C)=NC3=CC=C(C=C)C=C3N2C=1C1=C(F)C=CC=C1Cl ADCUCKZPYWAEBQ-UHFFFAOYSA-N 0.000 description 1
- FDJDXMSUDXBHSQ-UHFFFAOYSA-N 1-(2-chlorophenyl)-4-methyl-7-(2-pyridin-2-ylethoxy)-[1,2,4]triazolo[4,3-a]quinoxaline Chemical compound C=1C=C2N3C(C=4C(=CC=CC=4)Cl)=NN=C3C(C)=NC2=CC=1OCCC1=CC=CC=N1 FDJDXMSUDXBHSQ-UHFFFAOYSA-N 0.000 description 1
- ZLNBADYTIGPAFU-UHFFFAOYSA-N 1-(2-chlorophenyl)-4-methyl-7-(trifluoromethoxy)-[1,2,4]triazolo[4,3-a]quinoxaline Chemical compound N=1N=C2C(C)=NC3=CC(OC(F)(F)F)=CC=C3N2C=1C1=CC=CC=C1Cl ZLNBADYTIGPAFU-UHFFFAOYSA-N 0.000 description 1
- RSAPMUKAYVUXCU-UHFFFAOYSA-N 1-(2-chlorophenyl)-4-methyl-8-(2-pyridin-2-ylethoxy)-[1,2,4]triazolo[4,3-a]quinoxaline Chemical compound C1=C2N3C(C=4C(=CC=CC=4)Cl)=NN=C3C(C)=NC2=CC=C1OCCC1=CC=CC=N1 RSAPMUKAYVUXCU-UHFFFAOYSA-N 0.000 description 1
- PNYVWIGFSKFFAW-UHFFFAOYSA-N 1-(2-chlorophenyl)-4-methyl-8-(4-methylpiperazin-1-yl)-[1,2,4]triazolo[4,3-a]quinoxaline Chemical compound C1CN(C)CCN1C1=CC=C(N=C(C)C=2N3C(C=4C(=CC=CC=4)Cl)=NN=2)C3=C1 PNYVWIGFSKFFAW-UHFFFAOYSA-N 0.000 description 1
- MMWSLKUAHUNFRG-UHFFFAOYSA-N 1-(2-chlorophenyl)-4-methyl-8-(trifluoromethoxy)-[1,2,4]triazolo[4,3-a]quinoxaline Chemical compound N=1N=C2C(C)=NC3=CC=C(OC(F)(F)F)C=C3N2C=1C1=CC=CC=C1Cl MMWSLKUAHUNFRG-UHFFFAOYSA-N 0.000 description 1
- QINZPNYWORORJH-UHFFFAOYSA-N 1-(2-chlorophenyl)-4-methyl-8-[(4-methylpiperazin-1-yl)methyl]-[1,2,4]triazolo[4,3-a]quinoxaline Chemical compound C1CN(C)CCN1CC1=CC=C(N=C(C)C=2N3C(C=4C(=CC=CC=4)Cl)=NN=2)C3=C1 QINZPNYWORORJH-UHFFFAOYSA-N 0.000 description 1
- RNDRKGWDIXCGGN-UHFFFAOYSA-N 1-(2-chlorophenyl)-4-methyl-[1,2,4]triazolo[4,3-a]quinoxalin-8-amine Chemical compound N=1N=C2C(C)=NC3=CC=C(N)C=C3N2C=1C1=CC=CC=C1Cl RNDRKGWDIXCGGN-UHFFFAOYSA-N 0.000 description 1
- UQIZGVMJUBAZMQ-UHFFFAOYSA-N 1-(2-chlorophenyl)-4-methyl-[1,2,4]triazolo[4,3-a]quinoxalin-8-ol Chemical compound N=1N=C2C(C)=NC3=CC=C(O)C=C3N2C=1C1=CC=CC=C1Cl UQIZGVMJUBAZMQ-UHFFFAOYSA-N 0.000 description 1
- CTBSIWZADWNGPL-UHFFFAOYSA-N 1-(2-chlorophenyl)-4-methyl-[1,2,4]triazolo[4,3-a]quinoxaline Chemical compound N=1N=C2C(C)=NC3=CC=CC=C3N2C=1C1=CC=CC=C1Cl CTBSIWZADWNGPL-UHFFFAOYSA-N 0.000 description 1
- BNSTYXVEOJNFJM-UHFFFAOYSA-N 1-(2-chlorophenyl)-4-methyl-[1,2,4]triazolo[4,3-a]quinoxaline-8-carboxylic acid Chemical compound N=1N=C2C(C)=NC3=CC=C(C(O)=O)C=C3N2C=1C1=CC=CC=C1Cl BNSTYXVEOJNFJM-UHFFFAOYSA-N 0.000 description 1
- OKUUWEOFPDWWAJ-UHFFFAOYSA-N 1-(2-chlorophenyl)-4-methyl-n-(1-methylpiperidin-4-yl)-[1,2,4]triazolo[4,3-a]quinoxalin-8-amine Chemical compound C1CN(C)CCC1NC1=CC=C(N=C(C)C=2N3C(C=4C(=CC=CC=4)Cl)=NN=2)C3=C1 OKUUWEOFPDWWAJ-UHFFFAOYSA-N 0.000 description 1
- FGXIRQDNKXCFIL-UHFFFAOYSA-N 1-(2-chlorophenyl)-4-methyl-n-(1-methylpiperidin-4-yl)-[1,2,4]triazolo[4,3-a]quinoxaline-8-carboxamide Chemical compound C1CN(C)CCC1NC(=O)C1=CC=C(N=C(C)C=2N3C(C=4C(=CC=CC=4)Cl)=NN=2)C3=C1 FGXIRQDNKXCFIL-UHFFFAOYSA-N 0.000 description 1
- LEZMGPUUKQUXJN-UHFFFAOYSA-N 1-(2-chlorophenyl)-4-methyl-n-(2-morpholin-4-ylethyl)-[1,2,4]triazolo[4,3-a]quinoxalin-8-amine Chemical compound C1=C2N3C(C=4C(=CC=CC=4)Cl)=NN=C3C(C)=NC2=CC=C1NCCN1CCOCC1 LEZMGPUUKQUXJN-UHFFFAOYSA-N 0.000 description 1
- IFWAHVQKYGJWGP-UHFFFAOYSA-N 1-(2-chlorophenyl)-4-methyl-n-(2-morpholin-4-ylethyl)-[1,2,4]triazolo[4,3-a]quinoxaline-8-carboxamide Chemical compound N=1N=C2C(C)=NC3=CC=C(C(=O)NCCN4CCOCC4)C=C3N2C=1C1=CC=CC=C1Cl IFWAHVQKYGJWGP-UHFFFAOYSA-N 0.000 description 1
- XNYYCWIPILCSBL-UHFFFAOYSA-N 1-(2-chlorophenyl)-4-methyl-n-(2-phenylethyl)-[1,2,4]triazolo[4,3-a]quinoxaline-8-carboxamide Chemical compound N=1N=C2C(C)=NC3=CC=C(C(=O)NCCC=4C=CC=CC=4)C=C3N2C=1C1=CC=CC=C1Cl XNYYCWIPILCSBL-UHFFFAOYSA-N 0.000 description 1
- RHFWGIGDAGTINL-UHFFFAOYSA-N 1-(2-chlorophenyl)-4-methyl-n-(2-piperidin-1-ylethyl)-[1,2,4]triazolo[4,3-a]quinoxaline-8-carboxamide Chemical compound N=1N=C2C(C)=NC3=CC=C(C(=O)NCCN4CCCCC4)C=C3N2C=1C1=CC=CC=C1Cl RHFWGIGDAGTINL-UHFFFAOYSA-N 0.000 description 1
- YUYKNZMIAJIBOA-UHFFFAOYSA-N 1-(2-chlorophenyl)-4-methyl-n-(2-pyridin-2-ylethyl)-[1,2,4]triazolo[4,3-a]quinoxalin-8-amine Chemical compound C1=C2N3C(C=4C(=CC=CC=4)Cl)=NN=C3C(C)=NC2=CC=C1NCCC1=CC=CC=N1 YUYKNZMIAJIBOA-UHFFFAOYSA-N 0.000 description 1
- KTVOIZSPBSYWIC-UHFFFAOYSA-N 1-(2-chlorophenyl)-4-methyl-n-(2-pyrrolidin-1-ylethyl)-[1,2,4]triazolo[4,3-a]quinoxaline-8-carboxamide Chemical compound N=1N=C2C(C)=NC3=CC=C(C(=O)NCCN4CCCC4)C=C3N2C=1C1=CC=CC=C1Cl KTVOIZSPBSYWIC-UHFFFAOYSA-N 0.000 description 1
- MGKVGJJPEDPCEQ-UHFFFAOYSA-N 1-(2-chlorophenyl)-4-methyl-n-(3,4,5-trimethoxyphenyl)-[1,2,4]triazolo[4,3-a]quinoxaline-8-carboxamide Chemical compound COC1=C(OC)C(OC)=CC(NC(=O)C=2C=C3N4C(C=5C(=CC=CC=5)Cl)=NN=C4C(C)=NC3=CC=2)=C1 MGKVGJJPEDPCEQ-UHFFFAOYSA-N 0.000 description 1
- AWMOIFLKHCCNSA-UHFFFAOYSA-N 1-(2-chlorophenyl)-4-methyl-n-(pyridin-2-ylmethyl)-[1,2,4]triazolo[4,3-a]quinoxaline-8-carboxamide Chemical compound N=1N=C2C(C)=NC3=CC=C(C(=O)NCC=4N=CC=CC=4)C=C3N2C=1C1=CC=CC=C1Cl AWMOIFLKHCCNSA-UHFFFAOYSA-N 0.000 description 1
- VYUJHYUPDPKIJI-UHFFFAOYSA-N 1-(2-chlorophenyl)-8-(1,1-difluoroethoxy)-4-methyl-[1,2,4]triazolo[4,3-a]quinoxaline Chemical compound N=1N=C2C(C)=NC3=CC=C(OC(C)(F)F)C=C3N2C=1C1=CC=CC=C1Cl VYUJHYUPDPKIJI-UHFFFAOYSA-N 0.000 description 1
- KYFKQTJBDJLLCX-UHFFFAOYSA-N 1-(2-chlorophenyl)-8-[(3-methoxypiperidin-1-yl)methyl]-4-methyl-[1,2,4]triazolo[4,3-a]quinoxaline Chemical compound C1C(OC)CCCN1CC1=CC=C(N=C(C)C=2N3C(C=4C(=CC=CC=4)Cl)=NN=2)C3=C1 KYFKQTJBDJLLCX-UHFFFAOYSA-N 0.000 description 1
- CPSWTJWDYWGXCK-UHFFFAOYSA-N 1-(2-chlorophenyl)-8-[(4-fluoropiperidin-1-yl)methyl]-4-methyl-[1,2,4]triazolo[4,3-a]quinoxaline Chemical compound C1=C2N3C(C=4C(=CC=CC=4)Cl)=NN=C3C(C)=NC2=CC=C1CN1CCC(F)CC1 CPSWTJWDYWGXCK-UHFFFAOYSA-N 0.000 description 1
- UZSLMTQHJNJZLV-UHFFFAOYSA-N 1-(2-chlorophenyl)-8-[(4-methoxypiperidin-1-yl)methyl]-4-methyl-[1,2,4]triazolo[4,3-a]quinoxaline Chemical compound C1CC(OC)CCN1CC1=CC=C(N=C(C)C=2N3C(C=4C(=CC=CC=4)Cl)=NN=2)C3=C1 UZSLMTQHJNJZLV-UHFFFAOYSA-N 0.000 description 1
- KHYIRYRWPBUBTC-UHFFFAOYSA-N 1-(2-chlorophenyl)-8-[[3-(methoxymethyl)pyrrolidin-1-yl]methyl]-4-methyl-[1,2,4]triazolo[4,3-a]quinoxaline Chemical compound C1C(COC)CCN1CC1=CC=C(N=C(C)C=2N3C(C=4C(=CC=CC=4)Cl)=NN=2)C3=C1 KHYIRYRWPBUBTC-UHFFFAOYSA-N 0.000 description 1
- WMIGIQZRGONALR-UHFFFAOYSA-N 1-(2-chlorophenyl)-8-ethenyl-4-methyl-[1,2,4]triazolo[4,3-a]quinoxaline Chemical compound N=1N=C2C(C)=NC3=CC=C(C=C)C=C3N2C=1C1=CC=CC=C1Cl WMIGIQZRGONALR-UHFFFAOYSA-N 0.000 description 1
- IQFAUAIVCNIZMA-UHFFFAOYSA-N 1-(2-chlorophenyl)-8-methoxy-4-methyl-[1,2,4]triazolo[4,3-a]quinoxaline Chemical compound N12C3=CC(OC)=CC=C3N=C(C)C2=NN=C1C1=CC=CC=C1Cl IQFAUAIVCNIZMA-UHFFFAOYSA-N 0.000 description 1
- GUTVZXOGCBCORY-UHFFFAOYSA-N 1-(2-chlorophenyl)-n,4-dimethyl-[1,2,4]triazolo[4,3-a]quinoxaline-8-carboxamide Chemical compound N12C3=CC(C(=O)NC)=CC=C3N=C(C)C2=NN=C1C1=CC=CC=C1Cl GUTVZXOGCBCORY-UHFFFAOYSA-N 0.000 description 1
- VWVKVFZRFDUMRX-UHFFFAOYSA-N 1-(2-chlorophenyl)-n,n,4-trimethyl-[1,2,4]triazolo[4,3-a]quinoxalin-8-amine Chemical compound N12C3=CC(N(C)C)=CC=C3N=C(C)C2=NN=C1C1=CC=CC=C1Cl VWVKVFZRFDUMRX-UHFFFAOYSA-N 0.000 description 1
- PKTLZXQQPTWMHC-UHFFFAOYSA-N 1-(2-chlorophenyl)-n-(2-fluoroethyl)-4-methyl-[1,2,4]triazolo[4,3-a]quinoxaline-8-carboxamide Chemical compound N=1N=C2C(C)=NC3=CC=C(C(=O)NCCF)C=C3N2C=1C1=CC=CC=C1Cl PKTLZXQQPTWMHC-UHFFFAOYSA-N 0.000 description 1
- OVXRFSFTWQJRAZ-UHFFFAOYSA-N 1-(2-chlorophenyl)-n-(2-hydroxyethyl)-4-methyl-[1,2,4]triazolo[4,3-a]quinoxaline-8-carboxamide Chemical compound N=1N=C2C(C)=NC3=CC=C(C(=O)NCCO)C=C3N2C=1C1=CC=CC=C1Cl OVXRFSFTWQJRAZ-UHFFFAOYSA-N 0.000 description 1
- OJADSQAKVCVDIT-UHFFFAOYSA-N 1-(2-chlorophenyl)-n-(2-methoxyethyl)-4-methyl-[1,2,4]triazolo[4,3-a]quinoxalin-8-amine Chemical compound N12C3=CC(NCCOC)=CC=C3N=C(C)C2=NN=C1C1=CC=CC=C1Cl OJADSQAKVCVDIT-UHFFFAOYSA-N 0.000 description 1
- YJFZEKFUCDMNNG-UHFFFAOYSA-N 1-(2-chlorophenyl)-n-(2-methoxyethyl)-4-methyl-[1,2,4]triazolo[4,3-a]quinoxaline-8-carboxamide Chemical compound N12C3=CC(C(=O)NCCOC)=CC=C3N=C(C)C2=NN=C1C1=CC=CC=C1Cl YJFZEKFUCDMNNG-UHFFFAOYSA-N 0.000 description 1
- IIJNPKDFXOKUPY-UHFFFAOYSA-N 1-(2-chlorophenyl)-n-[(4-fluoropyridin-2-yl)methyl]-4-methyl-[1,2,4]triazolo[4,3-a]quinoxaline-8-carboxamide Chemical compound N=1N=C2C(C)=NC3=CC=C(C(=O)NCC=4N=CC=C(F)C=4)C=C3N2C=1C1=CC=CC=C1Cl IIJNPKDFXOKUPY-UHFFFAOYSA-N 0.000 description 1
- WUDYWLZBZXXXMD-UHFFFAOYSA-N 1-(2-chlorophenyl)-n-[(6-fluoropyridin-2-yl)methyl]-4-methyl-[1,2,4]triazolo[4,3-a]quinoxaline-8-carboxamide Chemical compound N=1N=C2C(C)=NC3=CC=C(C(=O)NCC=4N=C(F)C=CC=4)C=C3N2C=1C1=CC=CC=C1Cl WUDYWLZBZXXXMD-UHFFFAOYSA-N 0.000 description 1
- SRITYIMQTYHWHI-UHFFFAOYSA-N 1-(2-chlorophenyl)-n-[2-(diethylamino)ethyl]-4-methyl-[1,2,4]triazolo[4,3-a]quinoxaline-8-carboxamide Chemical compound N12C3=CC(C(=O)NCCN(CC)CC)=CC=C3N=C(C)C2=NN=C1C1=CC=CC=C1Cl SRITYIMQTYHWHI-UHFFFAOYSA-N 0.000 description 1
- JHNQIJOFPJQWJX-UHFFFAOYSA-N 1-(2-chlorophenyl)-n-ethyl-4-methyl-[1,2,4]triazolo[4,3-a]quinoxaline-8-carboxamide Chemical compound N12C3=CC(C(=O)NCC)=CC=C3N=C(C)C2=NN=C1C1=CC=CC=C1Cl JHNQIJOFPJQWJX-UHFFFAOYSA-N 0.000 description 1
- JWUTVUKQJDFDSE-UHFFFAOYSA-N 1-(2-methoxyphenyl)-4-methyl-n-(pyridin-2-ylmethyl)-[1,2,4]triazolo[4,3-a]quinoxaline-8-carboxamide Chemical compound COC1=CC=CC=C1C1=NN=C2N1C1=CC(C(=O)NCC=3N=CC=CC=3)=CC=C1N=C2C JWUTVUKQJDFDSE-UHFFFAOYSA-N 0.000 description 1
- RMKCJJPZQJQEJH-UHFFFAOYSA-N 1-(5-butoxy-2-chlorophenyl)-4-methyl-8-(2-pyridin-3-ylethoxy)-[1,2,4]triazolo[4,3-a]quinoxaline Chemical compound CCCCOC1=CC=C(Cl)C(C=2N3C4=CC(OCCC=5C=NC=CC=5)=CC=C4N=C(C)C3=NN=2)=C1 RMKCJJPZQJQEJH-UHFFFAOYSA-N 0.000 description 1
- MMQGTSRDDFFUBC-UHFFFAOYSA-N 1-(5-butoxy-2-chlorophenyl)-4-methyl-8-(4-methylpiperazin-1-yl)-[1,2,4]triazolo[4,3-a]quinoxaline Chemical compound CCCCOC1=CC=C(Cl)C(C=2N3C4=CC(=CC=C4N=C(C)C3=NN=2)N2CCN(C)CC2)=C1 MMQGTSRDDFFUBC-UHFFFAOYSA-N 0.000 description 1
- HWEOCPNBTWYYMW-UHFFFAOYSA-N 1-(5-butoxy-2-chlorophenyl)-4-methyl-8-(pyrrolidin-1-ylmethyl)-[1,2,4]triazolo[4,3-a]quinoxaline Chemical compound CCCCOC1=CC=C(Cl)C(C=2N3C4=CC(CN5CCCC5)=CC=C4N=C(C)C3=NN=2)=C1 HWEOCPNBTWYYMW-UHFFFAOYSA-N 0.000 description 1
- PXXAALYWDIZMGZ-UHFFFAOYSA-N 1-(5-butoxy-2-chlorophenyl)-4-methyl-8-[(4-methylpiperazin-1-yl)methyl]-[1,2,4]triazolo[4,3-a]quinoxaline Chemical compound CCCCOC1=CC=C(Cl)C(C=2N3C4=CC(CN5CCN(C)CC5)=CC=C4N=C(C)C3=NN=2)=C1 PXXAALYWDIZMGZ-UHFFFAOYSA-N 0.000 description 1
- JMYZWLOOMRTTEP-UHFFFAOYSA-N 1-(5-butoxy-2-chlorophenyl)-8-[(4-fluoropiperidin-1-yl)methyl]-4-methyl-[1,2,4]triazolo[4,3-a]quinoxaline Chemical compound CCCCOC1=CC=C(Cl)C(C=2N3C4=CC(CN5CCC(F)CC5)=CC=C4N=C(C)C3=NN=2)=C1 JMYZWLOOMRTTEP-UHFFFAOYSA-N 0.000 description 1
- PFISWSGRVIUKTH-UHFFFAOYSA-N 1-(5-butoxy-2-fluorophenyl)-4-methyl-[1,2,4]triazolo[4,3-a]quinoxaline-7-carbonitrile Chemical compound CCCCOC1=CC=C(F)C(C=2N3C4=CC=C(C=C4N=C(C)C3=NN=2)C#N)=C1 PFISWSGRVIUKTH-UHFFFAOYSA-N 0.000 description 1
- KIEDFQWRZWIXHW-UHFFFAOYSA-N 1-(5-butoxy-2-fluorophenyl)-4-methyl-[1,2,4]triazolo[4,3-a]quinoxaline-8-carbonitrile Chemical compound CCCCOC1=CC=C(F)C(C=2N3C4=CC(=CC=C4N=C(C)C3=NN=2)C#N)=C1 KIEDFQWRZWIXHW-UHFFFAOYSA-N 0.000 description 1
- CZPHYYDBRSZQLO-UHFFFAOYSA-N 1-(5-butoxypyridin-3-yl)-4-methyl-8-(pyrrolidin-1-ylmethyl)-[1,2,4]triazolo[4,3-a]quinoxaline Chemical compound CCCCOC1=CN=CC(C=2N3C4=CC(CN5CCCC5)=CC=C4N=C(C)C3=NN=2)=C1 CZPHYYDBRSZQLO-UHFFFAOYSA-N 0.000 description 1
- ATLVGHFNDQLLKU-UHFFFAOYSA-N 1-(5-butoxypyridin-3-yl)-8-[(4-fluoropiperidin-1-yl)methyl]-4-methyl-[1,2,4]triazolo[4,3-a]quinoxaline Chemical compound CCCCOC1=CN=CC(C=2N3C4=CC(CN5CCC(F)CC5)=CC=C4N=C(C)C3=NN=2)=C1 ATLVGHFNDQLLKU-UHFFFAOYSA-N 0.000 description 1
- SULXBCRYOCJQQR-UHFFFAOYSA-N 1-(5-butoxypyridin-3-yl)-8-ethenyl-4-methyl-[1,2,4]triazolo[4,3-a]quinoxaline Chemical compound CCCCOC1=CN=CC(C=2N3C4=CC(C=C)=CC=C4N=C(C)C3=NN=2)=C1 SULXBCRYOCJQQR-UHFFFAOYSA-N 0.000 description 1
- AJSPTCIXWPDZQS-UHFFFAOYSA-N 1-(5-chloropyridin-3-yl)-4-methyl-[1,2,4]triazolo[4,3-a]quinoxaline Chemical compound N=1N=C2C(C)=NC3=CC=CC=C3N2C=1C1=CN=CC(Cl)=C1 AJSPTCIXWPDZQS-UHFFFAOYSA-N 0.000 description 1
- IGMOOVLKWXSJFK-UHFFFAOYSA-N 1-(5-methoxypyridin-3-yl)-4-methyl-8-(trifluoromethoxy)-[1,2,4]triazolo[4,3-a]quinoxaline Chemical compound COC1=CN=CC(C=2N3C4=CC(OC(F)(F)F)=CC=C4N=C(C)C3=NN=2)=C1 IGMOOVLKWXSJFK-UHFFFAOYSA-N 0.000 description 1
- CDCGFCNQTVJYFL-UHFFFAOYSA-N 1-(5-methoxypyridin-3-yl)-4-methyl-8-(trifluoromethyl)-[1,2,4]triazolo[4,3-a]quinoxaline Chemical compound COC1=CN=CC(C=2N3C4=CC(=CC=C4N=C(C)C3=NN=2)C(F)(F)F)=C1 CDCGFCNQTVJYFL-UHFFFAOYSA-N 0.000 description 1
- NDAIEAHJBPRDFW-UHFFFAOYSA-N 1-[1-(2-chloro-5-ethoxyphenyl)-4-methyl-[1,2,4]triazolo[4,3-a]quinoxalin-8-yl]-n,n-dimethylmethanamine Chemical compound CCOC1=CC=C(Cl)C(C=2N3C4=CC(CN(C)C)=CC=C4N=C(C)C3=NN=2)=C1 NDAIEAHJBPRDFW-UHFFFAOYSA-N 0.000 description 1
- VMGBREZRTHHNMB-UHFFFAOYSA-N 1-[1-(2-chloro-5-propan-2-yloxyphenyl)-4-methyl-[1,2,4]triazolo[4,3-a]quinoxalin-8-yl]-n,n-dimethylmethanamine Chemical compound CC(C)OC1=CC=C(Cl)C(C=2N3C4=CC(CN(C)C)=CC=C4N=C(C)C3=NN=2)=C1 VMGBREZRTHHNMB-UHFFFAOYSA-N 0.000 description 1
- BLJXRMKAAJLGJY-UHFFFAOYSA-N 1-[1-(2-chloro-5-propoxyphenyl)-4-methyl-[1,2,4]triazolo[4,3-a]quinoxalin-8-yl]-n,n-dimethylmethanamine Chemical compound CCCOC1=CC=C(Cl)C(C=2N3C4=CC(CN(C)C)=CC=C4N=C(C)C3=NN=2)=C1 BLJXRMKAAJLGJY-UHFFFAOYSA-N 0.000 description 1
- KTLGKXZSYXVVBQ-UHFFFAOYSA-N 1-[1-(2-chlorophenyl)-4-methyl-[1,2,4]triazolo[4,3-a]quinoxalin-8-yl]-2,2,2-trifluoroethanol Chemical compound N=1N=C2C(C)=NC3=CC=C(C(O)C(F)(F)F)C=C3N2C=1C1=CC=CC=C1Cl KTLGKXZSYXVVBQ-UHFFFAOYSA-N 0.000 description 1
- XEABXHPHIWCPSN-UHFFFAOYSA-N 1-[1-(2-chlorophenyl)-4-methyl-[1,2,4]triazolo[4,3-a]quinoxalin-8-yl]-n,n-dimethylmethanamine Chemical compound N12C3=CC(CN(C)C)=CC=C3N=C(C)C2=NN=C1C1=CC=CC=C1Cl XEABXHPHIWCPSN-UHFFFAOYSA-N 0.000 description 1
- HBHNASZPIMMBSP-UHFFFAOYSA-N 1-[1-(2-chlorophenyl)-4-methyl-[1,2,4]triazolo[4,3-a]quinoxalin-8-yl]-n-ethyl-2,2,2-trifluoroethanamine Chemical compound N12C3=CC(C(NCC)C(F)(F)F)=CC=C3N=C(C)C2=NN=C1C1=CC=CC=C1Cl HBHNASZPIMMBSP-UHFFFAOYSA-N 0.000 description 1
- LFPMUKYZLLOJCK-UHFFFAOYSA-N 1-[1-(5-butoxy-2-chlorophenyl)-4-methyl-[1,2,4]triazolo[4,3-a]quinoxalin-8-yl]-n,n-dimethylmethanamine Chemical compound CCCCOC1=CC=C(Cl)C(C=2N3C4=CC(CN(C)C)=CC=C4N=C(C)C3=NN=2)=C1 LFPMUKYZLLOJCK-UHFFFAOYSA-N 0.000 description 1
- SRNXYBWTUXBFQS-UHFFFAOYSA-N 1-[1-(5-butoxy-2-chlorophenyl)-4-methyl-[1,2,4]triazolo[4,3-a]quinoxalin-8-yl]-n-methylmethanamine Chemical compound CCCCOC1=CC=C(Cl)C(C=2N3C4=CC(CNC)=CC=C4N=C(C)C3=NN=2)=C1 SRNXYBWTUXBFQS-UHFFFAOYSA-N 0.000 description 1
- BXZOMMFMRNCLGL-UHFFFAOYSA-N 1-[1-(5-butoxypyridin-3-yl)-4-methyl-[1,2,4]triazolo[4,3-a]quinoxalin-8-yl]-n,n-dimethylmethanamine Chemical compound CCCCOC1=CN=CC(C=2N3C4=CC(CN(C)C)=CC=C4N=C(C)C3=NN=2)=C1 BXZOMMFMRNCLGL-UHFFFAOYSA-N 0.000 description 1
- YGIXIOXEHQAKBB-UHFFFAOYSA-N 1-[1-(5-butoxypyridin-3-yl)-4-methyl-[1,2,4]triazolo[4,3-a]quinoxalin-8-yl]-n-methylmethanamine Chemical compound CCCCOC1=CN=CC(C=2N3C4=CC(CNC)=CC=C4N=C(C)C3=NN=2)=C1 YGIXIOXEHQAKBB-UHFFFAOYSA-N 0.000 description 1
- KDLJETKCCNQONU-UHFFFAOYSA-N 1-[1-[5-(cyclopropylmethoxy)pyridin-3-yl]-4-methyl-[1,2,4]triazolo[4,3-a]quinoxalin-8-yl]-n,n-dimethylmethanamine Chemical compound N12C3=CC(CN(C)C)=CC=C3N=C(C)C2=NN=C1C(C=1)=CN=CC=1OCC1CC1 KDLJETKCCNQONU-UHFFFAOYSA-N 0.000 description 1
- GCDYIBKSDWHAEM-UHFFFAOYSA-N 1-[5-(cyclopropylmethoxy)pyridin-3-yl]-4-methyl-8-(pyrrolidin-1-ylmethyl)-[1,2,4]triazolo[4,3-a]quinoxaline Chemical compound C1=C2N3C(C=4C=C(OCC5CC5)C=NC=4)=NN=C3C(C)=NC2=CC=C1CN1CCCC1 GCDYIBKSDWHAEM-UHFFFAOYSA-N 0.000 description 1
- GBHVIGQENJZEGX-UHFFFAOYSA-N 1-[[1-(2-chloro-5-ethoxyphenyl)-4-methyl-[1,2,4]triazolo[4,3-a]quinoxalin-8-yl]methyl]piperidin-4-ol Chemical compound CCOC1=CC=C(Cl)C(C=2N3C4=CC(CN5CCC(O)CC5)=CC=C4N=C(C)C3=NN=2)=C1 GBHVIGQENJZEGX-UHFFFAOYSA-N 0.000 description 1
- UNICJUYOQQVHAZ-UHFFFAOYSA-N 1-[[1-(2-chloro-5-propan-2-yloxyphenyl)-4-methyl-[1,2,4]triazolo[4,3-a]quinoxalin-8-yl]methyl]piperidin-4-ol Chemical compound CC(C)OC1=CC=C(Cl)C(C=2N3C4=CC(CN5CCC(O)CC5)=CC=C4N=C(C)C3=NN=2)=C1 UNICJUYOQQVHAZ-UHFFFAOYSA-N 0.000 description 1
- CBYKYFOMDUTGTG-UHFFFAOYSA-N 1-[[1-(2-chlorophenyl)-4-methyl-[1,2,4]triazolo[4,3-a]quinoxalin-8-yl]methyl]-n,n-dimethylpiperidin-4-amine Chemical compound C1CC(N(C)C)CCN1CC1=CC=C(N=C(C)C=2N3C(C=4C(=CC=CC=4)Cl)=NN=2)C3=C1 CBYKYFOMDUTGTG-UHFFFAOYSA-N 0.000 description 1
- YCWMKHFHOBOJHS-UHFFFAOYSA-N 1-[[1-(2-chlorophenyl)-4-methyl-[1,2,4]triazolo[4,3-a]quinoxalin-8-yl]methyl]piperidin-3-ol Chemical compound C1=C2N3C(C=4C(=CC=CC=4)Cl)=NN=C3C(C)=NC2=CC=C1CN1CCCC(O)C1 YCWMKHFHOBOJHS-UHFFFAOYSA-N 0.000 description 1
- OIOIOFDJPMGWSE-UHFFFAOYSA-N 1-[[1-(2-chlorophenyl)-4-methyl-[1,2,4]triazolo[4,3-a]quinoxalin-8-yl]methyl]piperidin-4-ol Chemical compound C1=C2N3C(C=4C(=CC=CC=4)Cl)=NN=C3C(C)=NC2=CC=C1CN1CCC(O)CC1 OIOIOFDJPMGWSE-UHFFFAOYSA-N 0.000 description 1
- JLLMMQQXVRIGOZ-UHFFFAOYSA-N 1-[[1-(2-chlorophenyl)-4-methyl-[1,2,4]triazolo[4,3-a]quinoxalin-8-yl]methyl]pyrrolidin-3-ol Chemical compound C1=C2N3C(C=4C(=CC=CC=4)Cl)=NN=C3C(C)=NC2=CC=C1CN1CCC(O)C1 JLLMMQQXVRIGOZ-UHFFFAOYSA-N 0.000 description 1
- FSCIQUOKFKVFRY-UHFFFAOYSA-N 1-[[1-(5-butoxy-2-chlorophenyl)-4-methyl-[1,2,4]triazolo[4,3-a]quinoxalin-8-yl]methyl]piperidin-4-ol Chemical compound CCCCOC1=CC=C(Cl)C(C=2N3C4=CC(CN5CCC(O)CC5)=CC=C4N=C(C)C3=NN=2)=C1 FSCIQUOKFKVFRY-UHFFFAOYSA-N 0.000 description 1
- KFTLKVVMSXUDGJ-UHFFFAOYSA-N 2-phenylethyl 4-methyl-1-phenyl-[1,2,4]triazolo[4,3-a]quinoxaline-8-carboxylate Chemical compound N=1N=C2C(C)=NC3=CC=C(C(=O)OCCC=4C=CC=CC=4)C=C3N2C=1C1=CC=CC=C1 KFTLKVVMSXUDGJ-UHFFFAOYSA-N 0.000 description 1
- SGHKMBWVNBLMNC-UHFFFAOYSA-N 3-phenylpropyl 4-methyl-1-phenyl-[1,2,4]triazolo[4,3-a]quinoxaline-8-carboxylate Chemical compound N=1N=C2C(C)=NC3=CC=C(C(=O)OCCCC=4C=CC=CC=4)C=C3N2C=1C1=CC=CC=C1 SGHKMBWVNBLMNC-UHFFFAOYSA-N 0.000 description 1
- PDOPFYRTIVSUKL-UHFFFAOYSA-N 4-(azepan-1-yl)-[1,2,4]triazolo[4,3-a]quinoxaline Chemical compound C1CCCCCN1C1=NC2=CC=CC=C2N2C1=NN=C2 PDOPFYRTIVSUKL-UHFFFAOYSA-N 0.000 description 1
- LNWOPNAAKIWAGD-UHFFFAOYSA-N 4-[1-[1-(2-chlorophenyl)-4-methyl-[1,2,4]triazolo[4,3-a]quinoxalin-8-yl]-2,2,2-trifluoroethyl]morpholine Chemical compound N=1N=C2C(C)=NC3=CC=C(C(N4CCOCC4)C(F)(F)F)C=C3N2C=1C1=CC=CC=C1Cl LNWOPNAAKIWAGD-UHFFFAOYSA-N 0.000 description 1
- HNVOBUPJZXUUSK-UHFFFAOYSA-N 4-[2-[[1-(2-chlorophenyl)-4-methyl-[1,2,4]triazolo[4,3-a]quinoxalin-8-yl]oxy]ethyl]morpholine Chemical compound C1=C2N3C(C=4C(=CC=CC=4)Cl)=NN=C3C(C)=NC2=CC=C1OCCN1CCOCC1 HNVOBUPJZXUUSK-UHFFFAOYSA-N 0.000 description 1
- VXJBJRPOPQUACF-UHFFFAOYSA-N 4-[[1-(2-chloro-4-fluorophenyl)-4-methyl-[1,2,4]triazolo[4,3-a]quinoxalin-8-yl]methyl]morpholine Chemical compound C1=C2N3C(C=4C(=CC(F)=CC=4)Cl)=NN=C3C(C)=NC2=CC=C1CN1CCOCC1 VXJBJRPOPQUACF-UHFFFAOYSA-N 0.000 description 1
- PQYOTCFMIISAPG-UHFFFAOYSA-N 4-[[1-(2-chloro-5-ethoxyphenyl)-4-methyl-[1,2,4]triazolo[4,3-a]quinoxalin-8-yl]methyl]morpholine Chemical compound CCOC1=CC=C(Cl)C(C=2N3C4=CC(CN5CCOCC5)=CC=C4N=C(C)C3=NN=2)=C1 PQYOTCFMIISAPG-UHFFFAOYSA-N 0.000 description 1
- VDIAEIJDVYOMLE-UHFFFAOYSA-N 4-[[1-(2-chloro-5-methoxyphenyl)-4-methyl-[1,2,4]triazolo[4,3-a]quinoxalin-8-yl]methyl]morpholine Chemical compound COC1=CC=C(Cl)C(C=2N3C4=CC(CN5CCOCC5)=CC=C4N=C(C)C3=NN=2)=C1 VDIAEIJDVYOMLE-UHFFFAOYSA-N 0.000 description 1
- JBSVWNORKAJZAE-UHFFFAOYSA-N 4-[[1-(2-chloro-5-propan-2-yloxyphenyl)-4-methyl-[1,2,4]triazolo[4,3-a]quinoxalin-8-yl]methyl]morpholine Chemical compound CC(C)OC1=CC=C(Cl)C(C=2N3C4=CC(CN5CCOCC5)=CC=C4N=C(C)C3=NN=2)=C1 JBSVWNORKAJZAE-UHFFFAOYSA-N 0.000 description 1
- AFHVGEIXWXGUNT-UHFFFAOYSA-N 4-[[1-(2-chloro-5-propoxyphenyl)-4-methyl-[1,2,4]triazolo[4,3-a]quinoxalin-8-yl]methyl]morpholine Chemical compound CCCOC1=CC=C(Cl)C(C=2N3C4=CC(CN5CCOCC5)=CC=C4N=C(C)C3=NN=2)=C1 AFHVGEIXWXGUNT-UHFFFAOYSA-N 0.000 description 1
- BXKLAYQKTVKJCY-VNRZBHCFSA-N 4-[[1-(2-chloro-6-fluoranylphenyl)-4-methyl-[1,2,4]triazolo[4,3-a]quinoxalin-8-yl]methyl]morpholine Chemical compound C1=C2N3C(C=4C(=CC=CC=4[18F])Cl)=NN=C3C(C)=NC2=CC=C1CN1CCOCC1 BXKLAYQKTVKJCY-VNRZBHCFSA-N 0.000 description 1
- BXKLAYQKTVKJCY-UHFFFAOYSA-N 4-[[1-(2-chloro-6-fluorophenyl)-4-methyl-[1,2,4]triazolo[4,3-a]quinoxalin-8-yl]methyl]morpholine Chemical compound C1=C2N3C(C=4C(=CC=CC=4F)Cl)=NN=C3C(C)=NC2=CC=C1CN1CCOCC1 BXKLAYQKTVKJCY-UHFFFAOYSA-N 0.000 description 1
- INCSVUYCNVZRDA-UHFFFAOYSA-N 4-[[1-(2-chlorophenyl)-4-methyl-[1,2,4]triazolo[4,3-a]quinoxalin-8-yl]methyl]-2-(2-fluoroethyl)morpholine Chemical compound C1=C2N3C(C=4C(=CC=CC=4)Cl)=NN=C3C(C)=NC2=CC=C1CN1CCOC(CCF)C1 INCSVUYCNVZRDA-UHFFFAOYSA-N 0.000 description 1
- APEPKKHCYXRSQK-UHFFFAOYSA-N 4-[[1-(2-chlorophenyl)-4-methyl-[1,2,4]triazolo[4,3-a]quinoxalin-8-yl]methyl]-2-(2-methoxyethyl)morpholine Chemical compound C1COC(CCOC)CN1CC1=CC=C(N=C(C)C=2N3C(C=4C(=CC=CC=4)Cl)=NN=2)C3=C1 APEPKKHCYXRSQK-UHFFFAOYSA-N 0.000 description 1
- ZQQQCGMZTQYBOM-UHFFFAOYSA-N 4-[[1-(2-chlorophenyl)-4-methyl-[1,2,4]triazolo[4,3-a]quinoxalin-8-yl]methyl]-2-(fluoromethyl)morpholine Chemical compound C1=C2N3C(C=4C(=CC=CC=4)Cl)=NN=C3C(C)=NC2=CC=C1CN1CCOC(CF)C1 ZQQQCGMZTQYBOM-UHFFFAOYSA-N 0.000 description 1
- BDTNXPSVJKURRR-UHFFFAOYSA-N 4-[[1-(2-chlorophenyl)-4-methyl-[1,2,4]triazolo[4,3-a]quinoxalin-8-yl]methyl]-2-(methoxymethyl)morpholine Chemical compound C1COC(COC)CN1CC1=CC=C(N=C(C)C=2N3C(C=4C(=CC=CC=4)Cl)=NN=2)C3=C1 BDTNXPSVJKURRR-UHFFFAOYSA-N 0.000 description 1
- LHZOEXXQXFAFRU-UHFFFAOYSA-N 4-[[1-(2-chlorophenyl)-4-methyl-[1,2,4]triazolo[4,3-a]quinoxalin-8-yl]methyl]-2-fluoro-2-(trifluoromethyl)morpholine Chemical compound C1=C2N3C(C=4C(=CC=CC=4)Cl)=NN=C3C(C)=NC2=CC=C1CN1CCOC(F)(C(F)(F)F)C1 LHZOEXXQXFAFRU-UHFFFAOYSA-N 0.000 description 1
- LZRGPVBUCASWQB-UHFFFAOYSA-N 4-[[1-(2-chlorophenyl)-4-methyl-[1,2,4]triazolo[4,3-a]quinoxalin-8-yl]methyl]morpholine Chemical compound C1=C2N3C(C=4C(=CC=CC=4)Cl)=NN=C3C(C)=NC2=CC=C1CN1CCOCC1 LZRGPVBUCASWQB-UHFFFAOYSA-N 0.000 description 1
- GSHAVWDELPHUJH-UHFFFAOYSA-N 4-[[1-(5-butoxy-2-chlorophenyl)-4-methyl-[1,2,4]triazolo[4,3-a]quinoxalin-8-yl]methyl]morpholine Chemical compound CCCCOC1=CC=C(Cl)C(C=2N3C4=CC(CN5CCOCC5)=CC=C4N=C(C)C3=NN=2)=C1 GSHAVWDELPHUJH-UHFFFAOYSA-N 0.000 description 1
- PKPRTWSDEQLHCM-UHFFFAOYSA-N 4-[[1-(5-butoxy-6-chloropyridin-3-yl)-4-methyl-[1,2,4]triazolo[4,3-a]quinoxalin-8-yl]methyl]morpholine Chemical compound N1=C(Cl)C(OCCCC)=CC(C=2N3C4=CC(CN5CCOCC5)=CC=C4N=C(C)C3=NN=2)=C1 PKPRTWSDEQLHCM-UHFFFAOYSA-N 0.000 description 1
- JJQZDOKXARNTKH-TZLORFPWSA-N 4-[[1-(5-butoxypyridin-3-yl)-4-methyl-[1,2,4]triazolo[4,3-a]quinoxalin-8-yl]-tritiomethyl]morpholine Chemical compound C=1C=C2N=C(C)C3=NN=C(C=4C=C(OCCCC)C=NC=4)N3C2=CC=1C([3H])N1CCOCC1 JJQZDOKXARNTKH-TZLORFPWSA-N 0.000 description 1
- JJQZDOKXARNTKH-UHFFFAOYSA-N 4-[[1-(5-butoxypyridin-3-yl)-4-methyl-[1,2,4]triazolo[4,3-a]quinoxalin-8-yl]methyl]morpholine Chemical compound CCCCOC1=CN=CC(C=2N3C4=CC(CN5CCOCC5)=CC=C4N=C(C)C3=NN=2)=C1 JJQZDOKXARNTKH-UHFFFAOYSA-N 0.000 description 1
- MUTVZBOSDNBOEV-UHFFFAOYSA-N 4-[[1-(5-methoxypyridin-3-yl)-4-methyl-[1,2,4]triazolo[4,3-a]quinoxalin-8-yl]methyl]morpholine Chemical compound COC1=CN=CC(C=2N3C4=CC(CN5CCOCC5)=CC=C4N=C(C)C3=NN=2)=C1 MUTVZBOSDNBOEV-UHFFFAOYSA-N 0.000 description 1
- NNSOUHQDSQHDRT-UHFFFAOYSA-N 4-[[1-[5-(2-fluoroethoxy)pyridin-3-yl]-4-methyl-[1,2,4]triazolo[4,3-a]quinoxalin-8-yl]methyl]morpholine Chemical compound C1=C2N3C(C=4C=C(OCCF)C=NC=4)=NN=C3C(C)=NC2=CC=C1CN1CCOCC1 NNSOUHQDSQHDRT-UHFFFAOYSA-N 0.000 description 1
- RBCNIKAFOHITAE-UHFFFAOYSA-N 4-[[1-[5-(2-methoxyethoxy)pyridin-3-yl]-4-methyl-[1,2,4]triazolo[4,3-a]quinoxalin-8-yl]methyl]morpholine Chemical compound COCCOC1=CN=CC(C=2N3C4=CC(CN5CCOCC5)=CC=C4N=C(C)C3=NN=2)=C1 RBCNIKAFOHITAE-UHFFFAOYSA-N 0.000 description 1
- TYTYHDPELCLVBA-UHFFFAOYSA-N 4-[[1-[5-(3-fluoropropoxy)pyridin-3-yl]-4-methyl-[1,2,4]triazolo[4,3-a]quinoxalin-8-yl]methyl]morpholine Chemical compound C1=C2N3C(C=4C=C(OCCCF)C=NC=4)=NN=C3C(C)=NC2=CC=C1CN1CCOCC1 TYTYHDPELCLVBA-UHFFFAOYSA-N 0.000 description 1
- GYCAHBYJOXOETE-UHFFFAOYSA-N 4-[[1-[5-(3-methoxypropyl)pyridin-3-yl]-4-methyl-[1,2,4]triazolo[4,3-a]quinoxalin-8-yl]methyl]morpholine Chemical compound COCCCC1=CN=CC(C=2N3C4=CC(CN5CCOCC5)=CC=C4N=C(C)C3=NN=2)=C1 GYCAHBYJOXOETE-UHFFFAOYSA-N 0.000 description 1
- ULBXWWOIYQZKIK-UHFFFAOYSA-N 4-[[1-[5-(ethoxymethyl)pyridin-3-yl]-4-methyl-[1,2,4]triazolo[4,3-a]quinoxalin-8-yl]methyl]morpholine Chemical compound CCOCC1=CN=CC(C=2N3C4=CC(CN5CCOCC5)=CC=C4N=C(C)C3=NN=2)=C1 ULBXWWOIYQZKIK-UHFFFAOYSA-N 0.000 description 1
- TVELNZSUPLTMOH-UHFFFAOYSA-N 4-[[4-methyl-1-(2-methylpyridin-3-yl)-[1,2,4]triazolo[4,3-a]quinoxalin-8-yl]methyl]morpholine Chemical compound CC1=NC=CC=C1C1=NN=C2N1C1=CC(CN3CCOCC3)=CC=C1N=C2C TVELNZSUPLTMOH-UHFFFAOYSA-N 0.000 description 1
- RXQBGBZOHKWYBQ-UHFFFAOYSA-N 4-[[4-methyl-1-(5-propoxypyridin-3-yl)-[1,2,4]triazolo[4,3-a]quinoxalin-8-yl]methyl]morpholine Chemical compound CCCOC1=CN=CC(C=2N3C4=CC(CN5CCOCC5)=CC=C4N=C(C)C3=NN=2)=C1 RXQBGBZOHKWYBQ-UHFFFAOYSA-N 0.000 description 1
- OSPAOFOZCVPMQA-UHFFFAOYSA-N 4-methyl-1-(2-methylpyridin-3-yl)-8-(trifluoromethoxy)-[1,2,4]triazolo[4,3-a]quinoxaline Chemical compound CC1=NC=CC=C1C1=NN=C2N1C1=CC(OC(F)(F)F)=CC=C1N=C2C OSPAOFOZCVPMQA-UHFFFAOYSA-N 0.000 description 1
- WJMGAKGFRQIMSW-UHFFFAOYSA-N 4-methyl-1-(2-methylpyridin-3-yl)-8-(trifluoromethyl)-[1,2,4]triazolo[4,3-a]quinoxaline Chemical compound CC1=NC=CC=C1C1=NN=C2N1C1=CC(C(F)(F)F)=CC=C1N=C2C WJMGAKGFRQIMSW-UHFFFAOYSA-N 0.000 description 1
- MNWBTFJCPUFSLK-UHFFFAOYSA-N 4-methyl-1-(2-methylpyridin-3-yl)-[1,2,4]triazolo[4,3-a]quinoxaline Chemical compound CC1=NC=CC=C1C1=NN=C2N1C1=CC=CC=C1N=C2C MNWBTFJCPUFSLK-UHFFFAOYSA-N 0.000 description 1
- ITHFELWCNWJUJU-UHFFFAOYSA-N 4-methyl-1-(5-methylpyridin-3-yl)-8-(trifluoromethyl)-[1,2,4]triazolo[4,3-a]quinoxaline Chemical compound CC1=CN=CC(C=2N3C4=CC(=CC=C4N=C(C)C3=NN=2)C(F)(F)F)=C1 ITHFELWCNWJUJU-UHFFFAOYSA-N 0.000 description 1
- STFUEDUBXBUOOF-UHFFFAOYSA-N 4-methyl-1-(5-methylpyridin-3-yl)-[1,2,4]triazolo[4,3-a]quinoxaline Chemical compound CC1=CN=CC(C=2N3C4=CC=CC=C4N=C(C)C3=NN=2)=C1 STFUEDUBXBUOOF-UHFFFAOYSA-N 0.000 description 1
- RJLICWCTMWNDHQ-UHFFFAOYSA-N 4-methyl-1-phenyl-[1,2,4]triazolo[4,3-a]quinoxaline-8-carboxylic acid Chemical compound N=1N=C2C(C)=NC3=CC=C(C(O)=O)C=C3N2C=1C1=CC=CC=C1 RJLICWCTMWNDHQ-UHFFFAOYSA-N 0.000 description 1
- ZFULJVQXYCCNKE-UHFFFAOYSA-N 4-methyl-1-phenyl-n-(2-phenylethyl)-[1,2,4]triazolo[4,3-a]quinoxaline-8-carboxamide Chemical compound N=1N=C2C(C)=NC3=CC=C(C(=O)NCCC=4C=CC=CC=4)C=C3N2C=1C1=CC=CC=C1 ZFULJVQXYCCNKE-UHFFFAOYSA-N 0.000 description 1
- FBLAQBPJSVGFII-UHFFFAOYSA-N 4-methyl-1-phenyl-n-(3-phenylpropyl)-[1,2,4]triazolo[4,3-a]quinoxaline-8-carboxamide Chemical compound N=1N=C2C(C)=NC3=CC=C(C(=O)NCCCC=4C=CC=CC=4)C=C3N2C=1C1=CC=CC=C1 FBLAQBPJSVGFII-UHFFFAOYSA-N 0.000 description 1
- MWOGXMHCBKOPQQ-UHFFFAOYSA-N 4-methyl-1-phenyl-n-(pyridin-2-ylmethyl)-[1,2,4]triazolo[4,3-a]quinoxaline-8-carboxamide Chemical compound N=1N=C2C(C)=NC3=CC=C(C(=O)NCC=4N=CC=CC=4)C=C3N2C=1C1=CC=CC=C1 MWOGXMHCBKOPQQ-UHFFFAOYSA-N 0.000 description 1
- QYYMHMXTKXJDBS-UHFFFAOYSA-N 4-methyl-1-phenyl-n-(pyridin-3-ylmethyl)-[1,2,4]triazolo[4,3-a]quinoxaline-8-carboxamide Chemical compound N=1N=C2C(C)=NC3=CC=C(C(=O)NCC=4C=NC=CC=4)C=C3N2C=1C1=CC=CC=C1 QYYMHMXTKXJDBS-UHFFFAOYSA-N 0.000 description 1
- BLGZTKFEGIQNDY-UHFFFAOYSA-N 4-methyl-1-phenyl-n-(pyridin-4-ylmethyl)-[1,2,4]triazolo[4,3-a]quinoxaline-8-carboxamide Chemical compound N=1N=C2C(C)=NC3=CC=C(C(=O)NCC=4C=CN=CC=4)C=C3N2C=1C1=CC=CC=C1 BLGZTKFEGIQNDY-UHFFFAOYSA-N 0.000 description 1
- HYZRBWOMKBCLRS-UHFFFAOYSA-N 4-methyl-8-(phenoxymethyl)-1-phenyl-[1,2,4]triazolo[4,3-a]quinoxaline Chemical compound C1=C2N3C(C=4C=CC=CC=4)=NN=C3C(C)=NC2=CC=C1COC1=CC=CC=C1 HYZRBWOMKBCLRS-UHFFFAOYSA-N 0.000 description 1
- KNRNBEGUVDNLBV-UHFFFAOYSA-N 7-bromo-1-(2-chlorophenyl)-4-methyl-[1,2,4]triazolo[4,3-a]quinoxaline Chemical compound N=1N=C2C(C)=NC3=CC(Br)=CC=C3N2C=1C1=CC=CC=C1Cl KNRNBEGUVDNLBV-UHFFFAOYSA-N 0.000 description 1
- UPDIRNSYQOPJKU-UHFFFAOYSA-N 7-bromo-1-(5-butoxy-2-chlorophenyl)-4-methyl-[1,2,4]triazolo[4,3-a]quinoxaline Chemical compound CCCCOC1=CC=C(Cl)C(C=2N3C4=CC=C(Br)C=C4N=C(C)C3=NN=2)=C1 UPDIRNSYQOPJKU-UHFFFAOYSA-N 0.000 description 1
- OUEVIWDWCUUCHD-UHFFFAOYSA-N 7-bromo-1-(5-butoxy-2-fluorophenyl)-4-methyl-[1,2,4]triazolo[4,3-a]quinoxaline Chemical compound CCCCOC1=CC=C(F)C(C=2N3C4=CC=C(Br)C=C4N=C(C)C3=NN=2)=C1 OUEVIWDWCUUCHD-UHFFFAOYSA-N 0.000 description 1
- CQZCPEJZRTXMSW-UHFFFAOYSA-N 8-(ethoxymethyl)-4-methyl-1-phenyl-[1,2,4]triazolo[4,3-a]quinoxaline Chemical compound N12C3=CC(COCC)=CC=C3N=C(C)C2=NN=C1C1=CC=CC=C1 CQZCPEJZRTXMSW-UHFFFAOYSA-N 0.000 description 1
- YBKHCZWQDPUACZ-UHFFFAOYSA-N 8-bromo-1-(2,3-dichlorophenyl)-4-methyl-[1,2,4]triazolo[4,3-a]quinoxaline Chemical compound N=1N=C2C(C)=NC3=CC=C(Br)C=C3N2C=1C1=CC=CC(Cl)=C1Cl YBKHCZWQDPUACZ-UHFFFAOYSA-N 0.000 description 1
- NUXISPFRNTYOGK-UHFFFAOYSA-N 8-bromo-1-(2,5-dichlorophenyl)-4-methyl-[1,2,4]triazolo[4,3-a]quinoxaline Chemical compound N=1N=C2C(C)=NC3=CC=C(Br)C=C3N2C=1C1=CC(Cl)=CC=C1Cl NUXISPFRNTYOGK-UHFFFAOYSA-N 0.000 description 1
- ZDIJUOBOIDUBPE-UHFFFAOYSA-N 8-bromo-1-(2-chloro-5-ethoxyphenyl)-4-methyl-[1,2,4]triazolo[4,3-a]quinoxaline Chemical compound CCOC1=CC=C(Cl)C(C=2N3C4=CC(Br)=CC=C4N=C(C)C3=NN=2)=C1 ZDIJUOBOIDUBPE-UHFFFAOYSA-N 0.000 description 1
- XRZVFFZEPRUUNF-UHFFFAOYSA-N 8-bromo-1-(2-chloro-5-methoxyphenyl)-4-methyl-[1,2,4]triazolo[4,3-a]quinoxaline Chemical compound COC1=CC=C(Cl)C(C=2N3C4=CC(Br)=CC=C4N=C(C)C3=NN=2)=C1 XRZVFFZEPRUUNF-UHFFFAOYSA-N 0.000 description 1
- FEZMGTPFCMFBNJ-UHFFFAOYSA-N 8-bromo-1-(2-chloro-5-propoxyphenyl)-4-methyl-[1,2,4]triazolo[4,3-a]quinoxaline Chemical compound CCCOC1=CC=C(Cl)C(C=2N3C4=CC(Br)=CC=C4N=C(C)C3=NN=2)=C1 FEZMGTPFCMFBNJ-UHFFFAOYSA-N 0.000 description 1
- HCIYBDDFKIFQGZ-UHFFFAOYSA-N 8-bromo-1-(2-chloro-6-fluorophenyl)-4-methyl-[1,2,4]triazolo[4,3-a]quinoxaline Chemical compound N=1N=C2C(C)=NC3=CC=C(Br)C=C3N2C=1C1=C(F)C=CC=C1Cl HCIYBDDFKIFQGZ-UHFFFAOYSA-N 0.000 description 1
- DQPTWPRWYXHDGO-UHFFFAOYSA-N 8-bromo-1-(2-chlorophenyl)-4-methyl-[1,2,4]triazolo[4,3-a]quinoxaline Chemical compound N=1N=C2C(C)=NC3=CC=C(Br)C=C3N2C=1C1=CC=CC=C1Cl DQPTWPRWYXHDGO-UHFFFAOYSA-N 0.000 description 1
- SFIXGLDTGNYPBL-UHFFFAOYSA-N 8-bromo-1-(5-butoxy-2-chlorophenyl)-4-methyl-[1,2,4]triazolo[4,3-a]quinoxaline Chemical compound CCCCOC1=CC=C(Cl)C(C=2N3C4=CC(Br)=CC=C4N=C(C)C3=NN=2)=C1 SFIXGLDTGNYPBL-UHFFFAOYSA-N 0.000 description 1
- PQXINFPHBGOGGU-UHFFFAOYSA-N 8-bromo-1-(5-butoxy-2-fluorophenyl)-4-methyl-[1,2,4]triazolo[4,3-a]quinoxaline Chemical compound CCCCOC1=CC=C(F)C(C=2N3C4=CC(Br)=CC=C4N=C(C)C3=NN=2)=C1 PQXINFPHBGOGGU-UHFFFAOYSA-N 0.000 description 1
- AUJUNLOZUFGEGD-UHFFFAOYSA-N 8-bromo-1-(5-butoxypyridin-3-yl)-4-methyl-[1,2,4]triazolo[4,3-a]quinoxaline Chemical compound CCCCOC1=CN=CC(C=2N3C4=CC(Br)=CC=C4N=C(C)C3=NN=2)=C1 AUJUNLOZUFGEGD-UHFFFAOYSA-N 0.000 description 1
- XHXPLDYBXUYOHZ-UHFFFAOYSA-N 8-bromo-1-(5-chloropyridin-3-yl)-4-methyl-[1,2,4]triazolo[4,3-a]quinoxaline Chemical compound N=1N=C2C(C)=NC3=CC=C(Br)C=C3N2C=1C1=CN=CC(Cl)=C1 XHXPLDYBXUYOHZ-UHFFFAOYSA-N 0.000 description 1
- VTCJWGQRODMDTE-UHFFFAOYSA-N 8-bromo-1-(5-methoxypyridin-3-yl)-4-methyl-[1,2,4]triazolo[4,3-a]quinoxaline Chemical compound COC1=CN=CC(C=2N3C4=CC(Br)=CC=C4N=C(C)C3=NN=2)=C1 VTCJWGQRODMDTE-UHFFFAOYSA-N 0.000 description 1
- CLDKFVHULZSNMB-UHFFFAOYSA-N 8-bromo-1-[5-(cyclopropylmethoxy)pyridin-3-yl]-4-methyl-[1,2,4]triazolo[4,3-a]quinoxaline Chemical compound N=1N=C2C(C)=NC3=CC=C(Br)C=C3N2C=1C(C=1)=CN=CC=1OCC1CC1 CLDKFVHULZSNMB-UHFFFAOYSA-N 0.000 description 1
- YAMSWNBYZYOMKC-UHFFFAOYSA-N 8-bromo-4-methyl-1-(2-methylpyridin-3-yl)-[1,2,4]triazolo[4,3-a]quinoxaline Chemical compound CC1=NC=CC=C1C1=NN=C2N1C1=CC(Br)=CC=C1N=C2C YAMSWNBYZYOMKC-UHFFFAOYSA-N 0.000 description 1
- RYSNNCCSSIJKTQ-UHFFFAOYSA-N 8-bromo-4-methyl-1-(4-methylpyridin-3-yl)-[1,2,4]triazolo[4,3-a]quinoxaline Chemical compound CC1=CC=NC=C1C1=NN=C2N1C1=CC(Br)=CC=C1N=C2C RYSNNCCSSIJKTQ-UHFFFAOYSA-N 0.000 description 1
- ZQZQJSNJBXJBRY-UHFFFAOYSA-N 8-bromo-4-methyl-1-(5-methylpyridin-3-yl)-[1,2,4]triazolo[4,3-a]quinoxaline Chemical compound CC1=CN=CC(C=2N3C4=CC(Br)=CC=C4N=C(C)C3=NN=2)=C1 ZQZQJSNJBXJBRY-UHFFFAOYSA-N 0.000 description 1
- NTQZQHOTDALRDO-UHFFFAOYSA-N 8-bromo-4-methyl-1-[2-(trifluoromethoxy)phenyl]-[1,2,4]triazolo[4,3-a]quinoxaline Chemical compound N=1N=C2C(C)=NC3=CC=C(Br)C=C3N2C=1C1=CC=CC=C1OC(F)(F)F NTQZQHOTDALRDO-UHFFFAOYSA-N 0.000 description 1
- IDINXJHHFWOVFM-UHFFFAOYSA-N 8-ethenyl-4-methyl-1-(4-methylpyridin-3-yl)-[1,2,4]triazolo[4,3-a]quinoxaline Chemical compound CC1=CC=NC=C1C1=NN=C2N1C1=CC(C=C)=CC=C1N=C2C IDINXJHHFWOVFM-UHFFFAOYSA-N 0.000 description 1
- WEYXJGDVURKFSL-UHFFFAOYSA-N 8-methoxy-4-methyl-1-(4-methylpyridin-3-yl)-[1,2,4]triazolo[4,3-a]quinoxaline Chemical compound N12C3=CC(OC)=CC=C3N=C(C)C2=NN=C1C1=CN=CC=C1C WEYXJGDVURKFSL-UHFFFAOYSA-N 0.000 description 1
- HVHHDNVBEAWEKV-UHFFFAOYSA-N 8-methoxy-4-methyl-1-[2-(trifluoromethoxy)phenyl]-[1,2,4]triazolo[4,3-a]quinoxaline Chemical compound N12C3=CC(OC)=CC=C3N=C(C)C2=NN=C1C1=CC=CC=C1OC(F)(F)F HVHHDNVBEAWEKV-UHFFFAOYSA-N 0.000 description 1
- WWDJFTHPKCEQHD-UHFFFAOYSA-N CC(C1OCCN(CC2=CC=C3N=C(C)C4=NN=C(C(C=CC=C5)=C5Cl)N4C3=C2)C1)O Chemical compound CC(C1OCCN(CC2=CC=C3N=C(C)C4=NN=C(C(C=CC=C5)=C5Cl)N4C3=C2)C1)O WWDJFTHPKCEQHD-UHFFFAOYSA-N 0.000 description 1
- DXWWBWCVHBJEHK-UHFFFAOYSA-N CC1=NC2=C(C=C(C=C2)Br)N3C1=NN=C3C4=C(C=CC(=C4)OC(C)OC)Cl Chemical compound CC1=NC2=C(C=C(C=C2)Br)N3C1=NN=C3C4=C(C=CC(=C4)OC(C)OC)Cl DXWWBWCVHBJEHK-UHFFFAOYSA-N 0.000 description 1
- XUOKIWXOOWOOMQ-UHFFFAOYSA-N CC1=NC2=C(C=C(C=C2)OCCC3=CN=CC=C3)N4C1=NN=C4C5=C(C=CC(=C5)OC(C)OC)Cl Chemical compound CC1=NC2=C(C=C(C=C2)OCCC3=CN=CC=C3)N4C1=NN=C4C5=C(C=CC(=C5)OC(C)OC)Cl XUOKIWXOOWOOMQ-UHFFFAOYSA-N 0.000 description 1
- NBBZSTXSWIIWDK-QAQDUYKDSA-N ClC1=C(C=CC=C1)C1=NN=C2N1C1=CC(=CC=C1N=C2C)CN[C@@H]2CC[C@H](CC2)O Chemical compound ClC1=C(C=CC=C1)C1=NN=C2N1C1=CC(=CC=C1N=C2C)CN[C@@H]2CC[C@H](CC2)O NBBZSTXSWIIWDK-QAQDUYKDSA-N 0.000 description 1
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
- MRIRZVKWJQGRQV-UHFFFAOYSA-N [1-(2-chlorophenyl)-4-methyl-[1,2,4]triazolo[4,3-a]quinoxalin-8-yl]-cyclopropylmethanone Chemical compound N=1N=C2C(C)=NC3=CC=C(C(=O)C4CC4)C=C3N2C=1C1=CC=CC=C1Cl MRIRZVKWJQGRQV-UHFFFAOYSA-N 0.000 description 1
- XYHOTKZGFKCGHN-UHFFFAOYSA-N [1-[[1-(2-chlorophenyl)-4-methyl-[1,2,4]triazolo[4,3-a]quinoxalin-8-yl]methyl]piperidin-3-yl]methanol Chemical compound C1=C2N3C(C=4C(=CC=CC=4)Cl)=NN=C3C(C)=NC2=CC=C1CN1CCCC(CO)C1 XYHOTKZGFKCGHN-UHFFFAOYSA-N 0.000 description 1
- ZBQNRSUAPBSMFO-UHFFFAOYSA-N [4-[[1-(2-chlorophenyl)-4-methyl-[1,2,4]triazolo[4,3-a]quinoxalin-8-yl]methyl]morpholin-2-yl]methanol Chemical compound C1=C2N3C(C=4C(=CC=CC=4)Cl)=NN=C3C(C)=NC2=CC=C1CN1CCOC(CO)C1 ZBQNRSUAPBSMFO-UHFFFAOYSA-N 0.000 description 1
- NCGASUCQDDAREU-UHFFFAOYSA-N benzyl 4-methyl-1-phenyl-[1,2,4]triazolo[4,3-a]quinoxaline-8-carboxylate Chemical compound N=1N=C2C(C)=NC3=CC=C(C(=O)OCC=4C=CC=CC=4)C=C3N2C=1C1=CC=CC=C1 NCGASUCQDDAREU-UHFFFAOYSA-N 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- GFZOJSHVIDTDPC-UHFFFAOYSA-N cyclopropyl-[4-methyl-1-(4-methylpyridin-3-yl)-[1,2,4]triazolo[4,3-a]quinoxalin-8-yl]methanone Chemical compound CC1=CC=NC=C1C1=NN=C2N1C1=CC(C(=O)C3CC3)=CC=C1N=C2C GFZOJSHVIDTDPC-UHFFFAOYSA-N 0.000 description 1
- 125000005745 ethoxymethyl group Chemical group [H]C([H])([H])C([H])([H])OC([H])([H])* 0.000 description 1
- OPVLYNGAOLVSGF-UHFFFAOYSA-N ethyl 1-(2-chlorophenyl)-4-methyl-[1,2,4]triazolo[4,3-a]quinoxaline-7-carboxylate Chemical compound C=1C(C(=O)OCC)=CC=C(N23)C=1N=C(C)C3=NN=C2C1=CC=CC=C1Cl OPVLYNGAOLVSGF-UHFFFAOYSA-N 0.000 description 1
- MKNKYIBULNNKQR-UHFFFAOYSA-N ethyl 1-(2-chlorophenyl)-4-methyl-[1,2,4]triazolo[4,3-a]quinoxaline-8-carboxylate Chemical compound N12C3=CC(C(=O)OCC)=CC=C3N=C(C)C2=NN=C1C1=CC=CC=C1Cl MKNKYIBULNNKQR-UHFFFAOYSA-N 0.000 description 1
- SKEZDIOVBYJCOV-UHFFFAOYSA-N ethyl 4-methyl-1-phenyl-[1,2,4]triazolo[4,3-a]quinoxaline-7-carboxylate Chemical compound C=1C(C(=O)OCC)=CC=C(N23)C=1N=C(C)C3=NN=C2C1=CC=CC=C1 SKEZDIOVBYJCOV-UHFFFAOYSA-N 0.000 description 1
- ZONQUSFKYYYHPU-UHFFFAOYSA-N ethyl 4-methyl-1-phenyl-[1,2,4]triazolo[4,3-a]quinoxaline-8-carboxylate Chemical compound N12C3=CC(C(=O)OCC)=CC=C3N=C(C)C2=NN=C1C1=CC=CC=C1 ZONQUSFKYYYHPU-UHFFFAOYSA-N 0.000 description 1
- FADBOWPXIRFCGQ-UHFFFAOYSA-N n-[1-(2-chlorophenyl)-4-methyl-[1,2,4]triazolo[4,3-a]quinoxalin-8-yl]propanamide Chemical compound N12C3=CC(NC(=O)CC)=CC=C3N=C(C)C2=NN=C1C1=CC=CC=C1Cl FADBOWPXIRFCGQ-UHFFFAOYSA-N 0.000 description 1
- BNCPRKFNMWSBJU-UHFFFAOYSA-N n-[[1-(2-chloro-5-ethoxyphenyl)-4-methyl-[1,2,4]triazolo[4,3-a]quinoxalin-8-yl]methyl]ethanamine Chemical compound N12C3=CC(CNCC)=CC=C3N=C(C)C2=NN=C1C1=CC(OCC)=CC=C1Cl BNCPRKFNMWSBJU-UHFFFAOYSA-N 0.000 description 1
- XIHPNKLIMDMEDL-UHFFFAOYSA-N n-[[1-(2-chloro-5-ethoxyphenyl)-4-methyl-[1,2,4]triazolo[4,3-a]quinoxalin-8-yl]methyl]pyridin-3-amine Chemical compound CCOC1=CC=C(Cl)C(C=2N3C4=CC(CNC=5C=NC=CC=5)=CC=C4N=C(C)C3=NN=2)=C1 XIHPNKLIMDMEDL-UHFFFAOYSA-N 0.000 description 1
- PKCYMHQCHPYQET-UHFFFAOYSA-N n-[[1-(2-chloro-5-propan-2-yloxyphenyl)-4-methyl-[1,2,4]triazolo[4,3-a]quinoxalin-8-yl]methyl]ethanamine Chemical compound N12C3=CC(CNCC)=CC=C3N=C(C)C2=NN=C1C1=CC(OC(C)C)=CC=C1Cl PKCYMHQCHPYQET-UHFFFAOYSA-N 0.000 description 1
- HWOZZQIWEJEHTR-UHFFFAOYSA-N n-[[1-(2-chloro-5-propan-2-yloxyphenyl)-4-methyl-[1,2,4]triazolo[4,3-a]quinoxalin-8-yl]methyl]pyridin-3-amine Chemical compound CC(C)OC1=CC=C(Cl)C(C=2N3C4=CC(CNC=5C=NC=CC=5)=CC=C4N=C(C)C3=NN=2)=C1 HWOZZQIWEJEHTR-UHFFFAOYSA-N 0.000 description 1
- MSHIPDFLJNFAJC-UHFFFAOYSA-N n-[[1-(2-chloro-5-propoxyphenyl)-4-methyl-[1,2,4]triazolo[4,3-a]quinoxalin-8-yl]methyl]ethanamine Chemical compound CCCOC1=CC=C(Cl)C(C=2N3C4=CC(CNCC)=CC=C4N=C(C)C3=NN=2)=C1 MSHIPDFLJNFAJC-UHFFFAOYSA-N 0.000 description 1
- ACJRYUPFLOVTGF-UHFFFAOYSA-N n-[[1-(2-chloro-5-propoxyphenyl)-4-methyl-[1,2,4]triazolo[4,3-a]quinoxalin-8-yl]methyl]pyridin-3-amine Chemical compound CCCOC1=CC=C(Cl)C(C=2N3C4=CC(CNC=5C=NC=CC=5)=CC=C4N=C(C)C3=NN=2)=C1 ACJRYUPFLOVTGF-UHFFFAOYSA-N 0.000 description 1
- LSOKSPALIMSVDM-UHFFFAOYSA-N n-[[1-(2-chlorophenyl)-4-methyl-[1,2,4]triazolo[4,3-a]quinoxalin-8-yl]methyl]-1-phenylmethanamine Chemical compound C1=C2N3C(C=4C(=CC=CC=4)Cl)=NN=C3C(C)=NC2=CC=C1CNCC1=CC=CC=C1 LSOKSPALIMSVDM-UHFFFAOYSA-N 0.000 description 1
- PMOYHZUHMRBKJN-UHFFFAOYSA-N n-[[1-(2-chlorophenyl)-4-methyl-[1,2,4]triazolo[4,3-a]quinoxalin-8-yl]methyl]ethanamine Chemical compound N12C3=CC(CNCC)=CC=C3N=C(C)C2=NN=C1C1=CC=CC=C1Cl PMOYHZUHMRBKJN-UHFFFAOYSA-N 0.000 description 1
- CHAYLLQTRFSAHL-UHFFFAOYSA-N n-[[1-(2-chlorophenyl)-4-methyl-[1,2,4]triazolo[4,3-a]quinoxalin-8-yl]methyl]oxan-4-amine Chemical compound C1=C2N3C(C=4C(=CC=CC=4)Cl)=NN=C3C(C)=NC2=CC=C1CNC1CCOCC1 CHAYLLQTRFSAHL-UHFFFAOYSA-N 0.000 description 1
- LQRKBCYOWUQCSE-UHFFFAOYSA-N n-[[1-(2-chlorophenyl)-4-methyl-[1,2,4]triazolo[4,3-a]quinoxalin-8-yl]methyl]pyridin-3-amine Chemical compound C1=C2N3C(C=4C(=CC=CC=4)Cl)=NN=C3C(C)=NC2=CC=C1CNC1=CC=CN=C1 LQRKBCYOWUQCSE-UHFFFAOYSA-N 0.000 description 1
- JMURPYMURQWSTJ-UHFFFAOYSA-N n-[[1-(5-butoxy-2-chlorophenyl)-4-methyl-[1,2,4]triazolo[4,3-a]quinoxalin-8-yl]methyl]-1-cyclopropylmethanamine Chemical compound CCCCOC1=CC=C(Cl)C(C=2N3C4=CC(CNCC5CC5)=CC=C4N=C(C)C3=NN=2)=C1 JMURPYMURQWSTJ-UHFFFAOYSA-N 0.000 description 1
- IYVNUVREPJDLRM-UHFFFAOYSA-N n-[[1-(5-butoxy-2-chlorophenyl)-4-methyl-[1,2,4]triazolo[4,3-a]quinoxalin-8-yl]methyl]cyclobutanamine Chemical compound CCCCOC1=CC=C(Cl)C(C=2N3C4=CC(CNC5CCC5)=CC=C4N=C(C)C3=NN=2)=C1 IYVNUVREPJDLRM-UHFFFAOYSA-N 0.000 description 1
- PIRQUJQMIKOECS-UHFFFAOYSA-N n-[[1-(5-butoxy-2-chlorophenyl)-4-methyl-[1,2,4]triazolo[4,3-a]quinoxalin-8-yl]methyl]ethanamine Chemical compound CCCCOC1=CC=C(Cl)C(C=2N3C4=CC(CNCC)=CC=C4N=C(C)C3=NN=2)=C1 PIRQUJQMIKOECS-UHFFFAOYSA-N 0.000 description 1
- RIDZVINUIPDLCQ-UHFFFAOYSA-N n-[[1-(5-butoxy-2-chlorophenyl)-4-methyl-[1,2,4]triazolo[4,3-a]quinoxalin-8-yl]methyl]propan-2-amine Chemical compound CCCCOC1=CC=C(Cl)C(C=2N3C4=CC(CNC(C)C)=CC=C4N=C(C)C3=NN=2)=C1 RIDZVINUIPDLCQ-UHFFFAOYSA-N 0.000 description 1
- JZNVXTPUTSWDLQ-UHFFFAOYSA-N n-[[1-(5-butoxypyridin-3-yl)-4-methyl-[1,2,4]triazolo[4,3-a]quinoxalin-8-yl]methyl]-1-cyclopropylmethanamine Chemical compound CCCCOC1=CN=CC(C=2N3C4=CC(CNCC5CC5)=CC=C4N=C(C)C3=NN=2)=C1 JZNVXTPUTSWDLQ-UHFFFAOYSA-N 0.000 description 1
- PWZRSAKOCVVTET-UHFFFAOYSA-N n-[[1-(5-butoxypyridin-3-yl)-4-methyl-[1,2,4]triazolo[4,3-a]quinoxalin-8-yl]methyl]cyclobutanamine Chemical compound CCCCOC1=CN=CC(C=2N3C4=CC(CNC5CCC5)=CC=C4N=C(C)C3=NN=2)=C1 PWZRSAKOCVVTET-UHFFFAOYSA-N 0.000 description 1
- XKVJQGZBJHTMTI-UHFFFAOYSA-N n-[[1-(5-butoxypyridin-3-yl)-4-methyl-[1,2,4]triazolo[4,3-a]quinoxalin-8-yl]methyl]ethanamine Chemical compound CCCCOC1=CN=CC(C=2N3C4=CC(CNCC)=CC=C4N=C(C)C3=NN=2)=C1 XKVJQGZBJHTMTI-UHFFFAOYSA-N 0.000 description 1
- BHMXFSJSWADVLS-UHFFFAOYSA-N n-[[1-(5-butoxypyridin-3-yl)-4-methyl-[1,2,4]triazolo[4,3-a]quinoxalin-8-yl]methyl]propan-2-amine Chemical compound CCCCOC1=CN=CC(C=2N3C4=CC(CNC(C)C)=CC=C4N=C(C)C3=NN=2)=C1 BHMXFSJSWADVLS-UHFFFAOYSA-N 0.000 description 1
- CXUDCXWYUYKHFN-UHFFFAOYSA-N n-[[1-[5-(cyclopropylmethoxy)pyridin-3-yl]-4-methyl-[1,2,4]triazolo[4,3-a]quinoxalin-8-yl]methyl]cyclobutanamine Chemical compound C1=C2N3C(C=4C=C(OCC5CC5)C=NC=4)=NN=C3C(C)=NC2=CC=C1CNC1CCC1 CXUDCXWYUYKHFN-UHFFFAOYSA-N 0.000 description 1
- ZHOGIIGEXYVVFK-UHFFFAOYSA-N n-[[1-[5-(cyclopropylmethoxy)pyridin-3-yl]-4-methyl-[1,2,4]triazolo[4,3-a]quinoxalin-8-yl]methyl]ethanamine Chemical compound N12C3=CC(CNCC)=CC=C3N=C(C)C2=NN=C1C(C=1)=CN=CC=1OCC1CC1 ZHOGIIGEXYVVFK-UHFFFAOYSA-N 0.000 description 1
- PVSWNXAQGIZVRS-UHFFFAOYSA-N n-[[1-[5-(ethoxymethyl)pyridin-3-yl]-4-methyl-[1,2,4]triazolo[4,3-a]quinoxalin-8-yl]methyl]cyclobutanamine Chemical compound CCOCC1=CN=CC(C=2N3C4=CC(CNC5CCC5)=CC=C4N=C(C)C3=NN=2)=C1 PVSWNXAQGIZVRS-UHFFFAOYSA-N 0.000 description 1
- OMJDTJPGMCDEOB-UHFFFAOYSA-N n-[[4-methyl-1-(5-propoxypyridin-3-yl)-[1,2,4]triazolo[4,3-a]quinoxalin-8-yl]methyl]cyclobutanamine Chemical compound CCCOC1=CN=CC(C=2N3C4=CC(CNC5CCC5)=CC=C4N=C(C)C3=NN=2)=C1 OMJDTJPGMCDEOB-UHFFFAOYSA-N 0.000 description 1
- YGNSXEDMBFIFRU-UHFFFAOYSA-N n-[[4-methyl-1-(5-propoxypyridin-3-yl)-[1,2,4]triazolo[4,3-a]quinoxalin-8-yl]methyl]ethanamine Chemical compound CCCOC1=CN=CC(C=2N3C4=CC(CNCC)=CC=C4N=C(C)C3=NN=2)=C1 YGNSXEDMBFIFRU-UHFFFAOYSA-N 0.000 description 1
- LPZCANRRYYLKAQ-UHFFFAOYSA-N n-benzyl-1-(2-chlorophenyl)-4-methyl-[1,2,4]triazolo[4,3-a]quinoxaline-8-carboxamide Chemical compound N=1N=C2C(C)=NC3=CC=C(C(=O)NCC=4C=CC=CC=4)C=C3N2C=1C1=CC=CC=C1Cl LPZCANRRYYLKAQ-UHFFFAOYSA-N 0.000 description 1
- BNPYRPMSUNIRRJ-UHFFFAOYSA-N n-benzyl-4-methyl-1-phenyl-[1,2,4]triazolo[4,3-a]quinoxaline-7-carboxamide Chemical compound N=1N=C2C(C)=NC3=CC(C(=O)NCC=4C=CC=CC=4)=CC=C3N2C=1C1=CC=CC=C1 BNPYRPMSUNIRRJ-UHFFFAOYSA-N 0.000 description 1
- HIUJNBXYERGONS-UHFFFAOYSA-N n-benzyl-4-methyl-1-phenyl-[1,2,4]triazolo[4,3-a]quinoxaline-8-carboxamide Chemical compound N=1N=C2C(C)=NC3=CC=C(C(=O)NCC=4C=CC=CC=4)C=C3N2C=1C1=CC=CC=C1 HIUJNBXYERGONS-UHFFFAOYSA-N 0.000 description 1
- LQSCREXWTVUPGQ-UHFFFAOYSA-N n-benzyl-n,4-dimethyl-1-phenyl-[1,2,4]triazolo[4,3-a]quinoxaline-8-carboxamide Chemical compound C=1C=C2N=C(C)C3=NN=C(C=4C=CC=CC=4)N3C2=CC=1C(=O)N(C)CC1=CC=CC=C1 LQSCREXWTVUPGQ-UHFFFAOYSA-N 0.000 description 1
- ASJRPPJEYHNNET-UHFFFAOYSA-N n-ethyl-1-(2-fluorophenyl)-4-methyl-[1,2,4]triazolo[4,3-a]quinoxaline-8-carboxamide Chemical compound N12C3=CC(C(=O)NCC)=CC=C3N=C(C)C2=NN=C1C1=CC=CC=C1F ASJRPPJEYHNNET-UHFFFAOYSA-N 0.000 description 1
- HXWSGMZHUJKHOE-UHFFFAOYSA-N n-ethyl-1-(2-methoxyphenyl)-4-methyl-[1,2,4]triazolo[4,3-a]quinoxaline-8-carboxamide Chemical compound N12C3=CC(C(=O)NCC)=CC=C3N=C(C)C2=NN=C1C1=CC=CC=C1OC HXWSGMZHUJKHOE-UHFFFAOYSA-N 0.000 description 1
- FEDOZVCITUGSNH-UHFFFAOYSA-N n-ethyl-1-(2-methoxypyridin-3-yl)-4-methyl-[1,2,4]triazolo[4,3-a]quinoxaline-7-carboxamide Chemical compound C=1C(C(=O)NCC)=CC=C(N23)C=1N=C(C)C3=NN=C2C1=CC=CN=C1OC FEDOZVCITUGSNH-UHFFFAOYSA-N 0.000 description 1
- QVUMIQCLVPRUBJ-UHFFFAOYSA-N n-ethyl-1-(2-methoxypyridin-3-yl)-4-methyl-[1,2,4]triazolo[4,3-a]quinoxaline-8-carboxamide Chemical compound N12C3=CC(C(=O)NCC)=CC=C3N=C(C)C2=NN=C1C1=CC=CN=C1OC QVUMIQCLVPRUBJ-UHFFFAOYSA-N 0.000 description 1
- NFLIWCYWMWIGMV-UHFFFAOYSA-N n-ethyl-1-(5-methoxypyridin-3-yl)-4-methyl-[1,2,4]triazolo[4,3-a]quinoxaline-7-carboxamide Chemical compound C=1C(C(=O)NCC)=CC=C(N23)C=1N=C(C)C3=NN=C2C1=CN=CC(OC)=C1 NFLIWCYWMWIGMV-UHFFFAOYSA-N 0.000 description 1
- UMJOYABDDYRKPH-UHFFFAOYSA-N n-ethyl-1-(5-methoxypyridin-3-yl)-4-methyl-[1,2,4]triazolo[4,3-a]quinoxaline-8-carboxamide Chemical compound N12C3=CC(C(=O)NCC)=CC=C3N=C(C)C2=NN=C1C1=CN=CC(OC)=C1 UMJOYABDDYRKPH-UHFFFAOYSA-N 0.000 description 1
- NZDZJCZDEDCEHQ-UHFFFAOYSA-N n-ethyl-4-methyl-1-(2-methylpyridin-3-yl)-[1,2,4]triazolo[4,3-a]quinoxaline-7-carboxamide Chemical compound C=1C(C(=O)NCC)=CC=C(N23)C=1N=C(C)C3=NN=C2C1=CC=CN=C1C NZDZJCZDEDCEHQ-UHFFFAOYSA-N 0.000 description 1
- GXLBTPXQMQEFQS-UHFFFAOYSA-N n-ethyl-4-methyl-1-(2-methylpyridin-3-yl)-[1,2,4]triazolo[4,3-a]quinoxaline-8-carboxamide Chemical compound N12C3=CC(C(=O)NCC)=CC=C3N=C(C)C2=NN=C1C1=CC=CN=C1C GXLBTPXQMQEFQS-UHFFFAOYSA-N 0.000 description 1
- MDTQFZDLEZMOSM-UHFFFAOYSA-N n-ethyl-4-methyl-1-(4-methylpyridin-3-yl)-[1,2,4]triazolo[4,3-a]quinoxaline-8-carboxamide Chemical compound N12C3=CC(C(=O)NCC)=CC=C3N=C(C)C2=NN=C1C1=CN=CC=C1C MDTQFZDLEZMOSM-UHFFFAOYSA-N 0.000 description 1
- PNBCGXHQDAXONB-UHFFFAOYSA-N n-ethyl-4-methyl-1-(6-methylpyridin-3-yl)-[1,2,4]triazolo[4,3-a]quinoxaline-8-carboxamide Chemical compound N12C3=CC(C(=O)NCC)=CC=C3N=C(C)C2=NN=C1C1=CC=C(C)N=C1 PNBCGXHQDAXONB-UHFFFAOYSA-N 0.000 description 1
- ZQOHAFYHYPKHNN-UHFFFAOYSA-N n-ethyl-4-methyl-1-phenyl-[1,2,4]triazolo[4,3-a]quinoxaline-8-carboxamide Chemical compound N12C3=CC(C(=O)NCC)=CC=C3N=C(C)C2=NN=C1C1=CC=CC=C1 ZQOHAFYHYPKHNN-UHFFFAOYSA-N 0.000 description 1
- CBPBGAAUJILPTQ-UHFFFAOYSA-N n-ethyl-4-methyl-1-pyridin-2-yl-[1,2,4]triazolo[4,3-a]quinoxaline-8-carboxamide Chemical compound N12C3=CC(C(=O)NCC)=CC=C3N=C(C)C2=NN=C1C1=CC=CC=N1 CBPBGAAUJILPTQ-UHFFFAOYSA-N 0.000 description 1
- DBZJUMHACWPWRD-UHFFFAOYSA-N n-ethyl-4-methyl-1-pyridin-3-yl-[1,2,4]triazolo[4,3-a]quinoxaline-8-carboxamide Chemical compound N12C3=CC(C(=O)NCC)=CC=C3N=C(C)C2=NN=C1C1=CC=CN=C1 DBZJUMHACWPWRD-UHFFFAOYSA-N 0.000 description 1
- LUPWGSHPWCTGJI-UHFFFAOYSA-N n-ethyl-4-methyl-1-pyridin-4-yl-[1,2,4]triazolo[4,3-a]quinoxaline-8-carboxamide Chemical compound N12C3=CC(C(=O)NCC)=CC=C3N=C(C)C2=NN=C1C1=CC=NC=C1 LUPWGSHPWCTGJI-UHFFFAOYSA-N 0.000 description 1
- 239000012453 solvate Substances 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP11171519 | 2011-06-27 | ||
| EP11171519.9 | 2011-06-27 | ||
| PCT/EP2012/062381 WO2013000924A1 (en) | 2011-06-27 | 2012-06-26 | 1-ARYL-4-METHYL-[1,2,4]TRIAZOLO[4,3-a]QUINOXALINE DERIVATIVES |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014518234A JP2014518234A (ja) | 2014-07-28 |
| JP2014518234A5 true JP2014518234A5 (cg-RX-API-DMAC7.html) | 2016-09-08 |
| JP6115962B2 JP6115962B2 (ja) | 2017-04-19 |
Family
ID=44370665
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014517667A Expired - Fee Related JP6115962B2 (ja) | 2011-06-27 | 2012-06-26 | 1−アリール−4−メチル−[1,2,4]トリアゾロ[4,3−a]キノキサリン誘導体 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US10604523B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP2723744B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP6115962B2 (cg-RX-API-DMAC7.html) |
| CN (1) | CN103619846B (cg-RX-API-DMAC7.html) |
| AU (1) | AU2012277912B2 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112013033375B1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2838645C (cg-RX-API-DMAC7.html) |
| EA (1) | EA027418B1 (cg-RX-API-DMAC7.html) |
| ES (1) | ES2575092T3 (cg-RX-API-DMAC7.html) |
| MX (1) | MX344600B (cg-RX-API-DMAC7.html) |
| WO (1) | WO2013000924A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9540379B2 (en) | 2011-01-31 | 2017-01-10 | Boehringer Ingelheim International Gmbh | (1,2,4)triazolo[4,3-A]quinoxaline derivatives as inhibitors of phosphodiesterases |
| JP6115962B2 (ja) | 2011-06-27 | 2017-04-19 | ヤンセン ファーマシューティカ エヌ.ベー. | 1−アリール−4−メチル−[1,2,4]トリアゾロ[4,3−a]キノキサリン誘導体 |
| US9056863B2 (en) * | 2011-09-09 | 2015-06-16 | H. Lundbeck A/S | Substituted 2,3,5,9,9B-pentaazacyclopenta[a]naphthalenes and uses thereof |
| WO2014001314A1 (en) * | 2012-06-26 | 2014-01-03 | Janssen Pharmaceutica Nv | Combinations comprising pde 2 inhibitors such as 1-aryl-4-methyl- [1,2,4] triazolo [4,3-a] quinoxaline compounds and pde 10 inhibitors for use in the treatment of neurological or metabolic disorders |
| US20140045856A1 (en) | 2012-07-31 | 2014-02-13 | Boehringer Ingelheim International Gmbh | 4-Methyl-2,3,5,9,9b-pentaaza-cyclopenta[a]naphthalenes |
| EP2951176A1 (en) * | 2013-01-31 | 2015-12-09 | F. Hoffmann-La Roche AG | Radiolabeled compounds |
| WO2014139983A1 (en) | 2013-03-13 | 2014-09-18 | H. Lundbeck A/S | [1,2,4]triazolo[4,3-a]quinoxalines as dual pde2/pde10 inhibitors |
| JP6696904B2 (ja) | 2014-01-08 | 2020-05-20 | イントラ−セルラー・セラピーズ・インコーポレイテッドIntra−Cellular Therapies, Inc. | 製剤および医薬組成物 |
| EP3134413B1 (en) | 2014-04-23 | 2019-09-11 | Dart NeuroScience (Cayman) Ltd. | Substituted [1,2,4]triazolo[1,5-a]pyrimidin-7-yl compounds as pde2 inhibitors |
| TWI568737B (zh) | 2014-11-05 | 2017-02-01 | 達特神經科學(開曼)有限責任公司 | 作為pde2抑制劑之經取代的5-甲基-[1,2,4]三唑并[1,5-a]嘧啶-2-胺化合物 |
| WO2016090382A1 (en) | 2014-12-06 | 2016-06-09 | Intra-Cellular Therapies, Inc. | Organic compounds |
| BR112017012007B1 (pt) | 2014-12-06 | 2022-11-01 | Intra-Cellular Therapies, Inc | Compostos orgânicos inibitórios de pde2, composições farmacêuticas compreendendo os ditos compostos e uso dos mesmos no tratamento de um distúrbio mediado por pde2 |
| WO2016145614A1 (en) | 2015-03-17 | 2016-09-22 | Merck Sharp & Dohme Corp. | Triazolyl pyrimidinone compounds as pde2 inhibitors |
| EP3285581B1 (en) | 2015-03-26 | 2021-08-11 | Merck Sharp & Dohme Corp. | Pyrazolyl pyrimidinone compounds as pde2 inhibitors |
| EP3291817B1 (en) | 2015-05-05 | 2019-10-02 | Merck Sharp & Dohme Corp. | Heteroaryl-pyrimidinone compounds as pde2 inhibitors |
| WO2016183741A1 (en) | 2015-05-15 | 2016-11-24 | Merck Sharp & Dohme Corp. | Pyrimidinone amide compounds as pde2 inhibitors |
| WO2016191935A1 (en) | 2015-05-29 | 2016-12-08 | Merck Sharp & Dohme Corp. | 6-alkyl dihydropyrazolopyrimidinone compounds as pde2 inhibitors |
| WO2016192083A1 (en) | 2015-06-04 | 2016-12-08 | Merck Sharp & Dohme Corp. | Dihydropyrazolopyrimidinone compounds as pde2 inhibitors |
| US10647727B2 (en) | 2015-06-25 | 2020-05-12 | Merck Sharp & Dohme Corp. | Substituted pyrazolo/imidazolo bicyclic compounds as PDE2 inhibitors |
| WO2017000277A1 (en) | 2015-07-01 | 2017-01-05 | Merck Sharp & Dohme Corp. | Substituted triazolo bicycliccompounds as pde2 inhibitors |
| WO2017000276A1 (en) | 2015-07-01 | 2017-01-05 | Merck Sharp & Dohme Corp. | Bicyclic heterocyclic compounds as pde2 inhibitors |
| EP3156405A1 (en) | 2015-10-13 | 2017-04-19 | Boehringer Ingelheim International GmbH | Spirocyclic ether derivatives of pyrazolo[1,5-a]pyrimidine-3-carboxamide |
| CA3001768C (en) * | 2015-11-02 | 2022-12-13 | Janssen Pharmaceutica Nv | [1,2,4]triazolo[1,5-a]pyrimidin-7-yl compound |
| WO2017165311A1 (en) * | 2016-03-21 | 2017-09-28 | Perlstein Lab Pbc | Fused heterocyclic organic compounds and uses thereof |
| WO2018083103A1 (en) | 2016-11-02 | 2018-05-11 | Janssen Pharmaceutica Nv | [1,2,4]triazolo[1,5-a]pyrimidine compounds as pde2 inhibitors |
| KR20190070972A (ko) | 2016-11-02 | 2019-06-21 | 얀센 파마슈티카 엔.브이. | Pde2 억제제로서의 [1,2,4]트리아졸로[1,5-a]피리미딘 유도체 |
| WO2018083101A1 (en) | 2016-11-02 | 2018-05-11 | Janssen Pharmaceutica Nv | [1,2,4]triazolo[1,5-a]pyrimidine compounds as pde2 inhibitors |
| CN107827828B (zh) * | 2017-11-21 | 2021-03-30 | 南京华漫新材料科技有限公司 | 含苯酰肼骨架的喹喔啉衍生物及其制备方法和在制备抗肿瘤药物中的应用 |
| US11419874B2 (en) | 2017-11-23 | 2022-08-23 | Oslo University Hospital Hf | Treatment of tachycardia |
Family Cites Families (214)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5584421A (en) | 1978-12-21 | 1980-06-25 | Mitsui Cokes Kogyo Kk | Method of making fibrous carbon |
| US4242513A (en) | 1979-03-05 | 1980-12-30 | Appleton Papers Inc. | Lactone compounds containing a heterocyclic radical |
| EP0226641B1 (en) | 1985-05-25 | 1989-10-18 | Yoshitomi Pharmaceutical Industries, Ltd. | Oxodiazine compounds |
| AU5921890A (en) | 1989-06-13 | 1991-01-08 | Smithkline Beecham Corporation | Monokine activity interference |
| KR920702621A (ko) | 1989-06-13 | 1992-10-06 | 스튜어트 알. 슈터 | 단핵세포 및/또는 마크로파지에 의한 인터루킨-1 또는 종양회사인자 생성의 억제 |
| AU622330B2 (en) | 1989-06-23 | 1992-04-02 | Takeda Chemical Industries Ltd. | Condensed heterocyclic compounds having a nitrogen atom in the bridgehead for use as fungicides |
| KR910011852A (ko) | 1989-12-04 | 1991-08-07 | 폴 디. 매튜카이티스 | 신경독 장해 치료용 이미다조[1,2-a]피리디닐알킬 화합물 |
| EP0533837A4 (en) | 1990-06-12 | 1994-11-17 | Smithkline Beecham Corp | Inhibition of 5-lipoxygenase and cyclooxygenase pathway mediated diseases |
| US5137876A (en) | 1990-10-12 | 1992-08-11 | Merck & Co., Inc. | Nucleoside antiviral and anti-inflammatory compounds and compositions and methods for using same |
| JPH06504779A (ja) | 1990-12-13 | 1994-06-02 | スミスクライン・ビーチャム・コーポレイション | 新規csaids |
| EP0563286A4 (en) | 1990-12-13 | 1995-01-11 | Smithkline Beecham Corp | Novel csaids |
| US5683998A (en) | 1991-04-23 | 1997-11-04 | Toray Industries, Inc. | Tricyclic triazolo derivatives, processes for producing the same and the uses of the same |
| CN1033327C (zh) * | 1991-04-23 | 1996-11-20 | 东丽株式会社 | 三环三唑并衍生物的制造方法 |
| DK31093D0 (cg-RX-API-DMAC7.html) * | 1993-03-19 | 1993-03-19 | Novo Nordisk As | |
| US5486525A (en) | 1993-12-16 | 1996-01-23 | Abbott Laboratories | Platelet activating factor antagonists: imidazopyridine indoles |
| US5869486A (en) | 1995-02-24 | 1999-02-09 | Ono Pharmaceutical Co., Ltd. | Fused pyrimidines and pyriazines as pharmaceutical compounds |
| AU5348396A (en) | 1995-05-01 | 1996-11-21 | Fujisawa Pharmaceutical Co., Ltd. | Imidazo 1,2-a pyridine and imidazo 1,2-a pyridezine derivati ves and their use as bone resorption inhibitors |
| US6992188B1 (en) | 1995-12-08 | 2006-01-31 | Pfizer, Inc. | Substituted heterocyclic derivatives |
| US20010007867A1 (en) | 1999-12-13 | 2001-07-12 | Yuhpyng L. Chen | Substituted 6,5-hetero-bicyclic derivatives |
| JP2001511813A (ja) | 1997-02-18 | 2001-08-14 | ニューロクライン バイオサイエンシーズ,インコーポレイテッド | Crfレセプターアンタゴニストおよびそれらに関連する方法 |
| AU6691798A (en) | 1997-03-07 | 1998-09-22 | Metabasis Therapeutics, Inc. | Novel indole and azaindole inhibitors of fructose-1,6-bisphosphatase |
| WO1999011643A1 (en) | 1997-09-02 | 1999-03-11 | Du Pont Pharmaceuticals Company | Heterocyclyl-substituted ring-fused pyridines and pyrimidines as corticotropin releasing hormone (crh) antagonists, useful for treating cns and stress-related disorders |
| EP1100504A2 (en) | 1998-07-02 | 2001-05-23 | Eisai Co., Ltd. | Pharmaceutical compositions and their uses for treatment of demyelinating disorders |
| US6248755B1 (en) | 1999-04-06 | 2001-06-19 | Merck & Co., Inc. | Pyrrolidine modulators of chemokine receptor activity |
| JP4032566B2 (ja) | 1999-06-21 | 2008-01-16 | 東レ株式会社 | 発光素子 |
| JP2001057292A (ja) | 1999-08-20 | 2001-02-27 | Toray Ind Inc | 発光素子 |
| GB9919778D0 (en) | 1999-08-21 | 1999-10-27 | Zeneca Ltd | Chemical compounds |
| IL139197A0 (en) | 1999-10-29 | 2001-11-25 | Pfizer Prod Inc | Use of corticotropin releasing factor antagonists and related compositions |
| KR20030016222A (ko) | 2000-02-14 | 2003-02-26 | 니뽄 다바코 산교 가부시키가이샤 | 수술후 스트레스 예방ㆍ치료제 |
| EP1149583A3 (en) | 2000-04-13 | 2001-11-14 | Pfizer Products Inc. | Combinations of corticotropin releasing factor antagonists and growth hormone secretagogues |
| US6403588B1 (en) | 2000-04-27 | 2002-06-11 | Yamanouchi Pharmaceutical Co., Ltd. | Imidazopyridine derivatives |
| EP1301511A2 (en) | 2000-07-14 | 2003-04-16 | Bristol-Myers Squibb Pharma Company | IMIDAZO 1,2-a]PYRAZINES FOR THE TREATMENT OF NEUROLOGICAL DISORDERS |
| WO2002034748A1 (fr) | 2000-10-24 | 2002-05-02 | Sankyo Company, Limited | Derives d'imidazopyridine |
| WO2002048146A2 (de) | 2000-12-13 | 2002-06-20 | Basf Aktiengesellschaft | Verwendung von substituierten imidazoazinen, neue imidazoazine, verfahren zu deren herstellung, sowie sie enthaltende mittel |
| MXPA03006514A (es) | 2001-01-22 | 2004-12-02 | Merck & Co Inc | Derivados de nucleosidos como inhibidores de polimerasa de acido ribonucleico viral dependiente de acido ribonucleico. |
| TWI312347B (en) | 2001-02-08 | 2009-07-21 | Eisai R&D Man Co Ltd | Bicyclic nitrogen-containing condensed ring compounds |
| GB0103926D0 (en) | 2001-02-17 | 2001-04-04 | Astrazeneca Ab | Chemical compounds |
| BR0207096A (pt) | 2001-02-20 | 2004-01-20 | Astrazeneca Ab | Uso de um composto, compostos, formulação farmacêutica, e, método de tratamento e/ou profilaxia de condições associadas com a inibição de glicogênio sintase quinase-3 |
| SE0100568D0 (sv) | 2001-02-20 | 2001-02-20 | Astrazeneca Ab | Compounds |
| AU2002258550B2 (en) | 2001-03-14 | 2006-04-27 | Eli Lilly And Company | Retinoid X receptor modulators |
| EP2048142A3 (en) | 2001-04-26 | 2009-04-22 | Eisai R&D Management Co., Ltd. | Nitrogen-containing condensed cyclic compound having a pyrazolyl group as a substituent group and pharmaceutical composition thereof |
| WO2002096363A2 (en) | 2001-05-30 | 2002-12-05 | Alteon, Inc. | Method for treating fibrotic diseases or other indications |
| US6806268B2 (en) | 2001-05-30 | 2004-10-19 | Alteon, Inc. | Method for treating glaucoma V |
| KR20040018281A (ko) | 2001-06-21 | 2004-03-02 | 스미스클라인 비참 코포레이션 | 포진 바이러스 감염의 예방 및 치료를 위한 이미다조[1,2-α]피리딘 유도체 |
| CA2450555A1 (en) | 2001-06-25 | 2003-01-03 | Merck & Co., Inc. | (pyrimidyl)(phenyl)substituted fused heteroaryl p38 inhibiting and pkg kinase inhibiting compounds |
| IL159811A0 (en) | 2001-07-13 | 2004-06-20 | Neurogen Corp | Heteroaryl substituted fused bicyclic heteroaryl compounds as gabaa receptor ligands |
| US7244740B2 (en) | 2001-10-05 | 2007-07-17 | Smithkline Beecham Corporation | Imidazo-pyridine derivatives for use in the treatment of herpes viral infection |
| JP2005529067A (ja) | 2002-01-22 | 2005-09-29 | メルク エンド カムパニー インコーポレーテッド | ケモカイン受容体ccr5モジュレータによるストレス応答の治療 |
| ES2276048T3 (es) | 2002-03-05 | 2007-06-16 | Eli Lilly And Company | Derivados de purina como inhibidores de cinasa. |
| JP2003313126A (ja) | 2002-04-23 | 2003-11-06 | Sankyo Co Ltd | イミダゾピリジン誘導体を有効成分とする医薬 |
| JP2004002826A (ja) | 2002-04-24 | 2004-01-08 | Sankyo Co Ltd | 高分子イミダゾピリジン誘導体 |
| CA2484631A1 (en) | 2002-05-13 | 2003-11-27 | Merck & Co., Inc. | Phenyl substituted imidazopyridines and phenyl substituted benzimidazoles |
| WO2003099840A1 (en) | 2002-05-24 | 2003-12-04 | Isis Pharmaceuticals, Inc. | Oligonucleotides having modified nucleoside units |
| GB0217783D0 (en) | 2002-07-31 | 2002-09-11 | Glaxo Group Ltd | Compounds |
| EP1539748A1 (en) | 2002-07-31 | 2005-06-15 | Smithkline Beecham Corporation | 2-phenylpyridin-4-yl derivatives as alk5 inhibitors |
| AU2003256297A1 (en) | 2002-08-09 | 2004-02-25 | Eli Lilly And Company | Benzimidazoles and benzothiazoles as inhibitors of map kinase |
| WO2004017950A2 (en) | 2002-08-22 | 2004-03-04 | Piramed Limited | Phosphadidylinositol 3,5-biphosphate inhibitors as anti-viral agents |
| UA80296C2 (en) | 2002-09-06 | 2007-09-10 | Biogen Inc | Imidazolopyridines and methods of making and using the same |
| AU2003270489A1 (en) | 2002-09-09 | 2004-03-29 | Cellular Genomics, Inc. | 6-ARYL-IMIDAZO(1,2-a)PYRAZIN-8-YLAMINES, METHOD OF MAKING, AND METHOD OF USE THEREOF |
| US7105533B2 (en) | 2002-09-13 | 2006-09-12 | Merck & Co., Inc. | Fused heterobicyclo substituted phenyl metabotropic glutamate-5 modulators |
| WO2004026867A2 (en) | 2002-09-19 | 2004-04-01 | Schering Corporation | Imidazopyridines as cyclin dependent kinase inhibitors |
| KR20060010709A (ko) | 2002-09-23 | 2006-02-02 | 쉐링 코포레이션 | 사이클린 의존성 키나제 억제제로서의 신규한 이미다조피라진 |
| US7576085B2 (en) | 2002-09-23 | 2009-08-18 | Schering Corporation | Imidazopyrazines as cyclin dependent kinase inhibitors |
| JP4799864B2 (ja) | 2002-09-23 | 2011-10-26 | シェーリング コーポレイション | サイクリン依存性キナーゼインヒビターとしてのイミダゾピラジン |
| WO2004035579A1 (ja) | 2002-10-15 | 2004-04-29 | Takeda Pharmaceutical Company Limited | イミダゾピリジン誘導体、その製造法および用途 |
| AU2003298658A1 (en) | 2002-11-15 | 2004-06-15 | Idenix (Cayman) Limited | 2'-branched nucleosides and flaviviridae mutation |
| US20070004736A1 (en) | 2002-11-22 | 2007-01-04 | Keiji Kubo | Imidazole derivative, process for producing the same, and use |
| KR101064077B1 (ko) | 2003-01-10 | 2011-09-08 | 이데미쓰 고산 가부시키가이샤 | 질소-함유 헤테로환 유도체 및 이를 이용한 유기 전기발광소자 |
| US7189723B2 (en) | 2003-02-10 | 2007-03-13 | Cgi Pharmaceuticals, Inc. | Certain 8-heteroaryl-6-phenyl-imidazo[1,2-a]pyrazines as modulators of kinase activity |
| US7186832B2 (en) | 2003-02-20 | 2007-03-06 | Sugen Inc. | Use of 8-amino-aryl-substituted imidazopyrazines as kinase inhibitors |
| US7329668B2 (en) | 2003-02-25 | 2008-02-12 | Bristol-Myers Squibb Company | Pyrazolopurine-based tricyclic compounds and pharmaceutical compositions comprising same |
| PA8595001A1 (es) | 2003-03-04 | 2004-09-28 | Pfizer Prod Inc | Nuevos compuestos heteroaromaticos condensados que son inhibidores del factor de crecimiento transforante (tgf) |
| US7041671B2 (en) | 2003-04-02 | 2006-05-09 | Pfizer Inc | Pyrrolo[1,2-b]pyridazine compounds and their uses |
| US20060094699A1 (en) | 2003-04-11 | 2006-05-04 | Kampen Gita Camilla T | Combination therapy using an 11beta-hydroxysteroid dehydrogenase type 1 inhibitor and a glucocorticoid receptor agonist to minimize the side effects associated with glucocorticoid receptor agonist therapy |
| US20060100235A1 (en) | 2003-04-11 | 2006-05-11 | Novo Nordisk A/S | Pharmaceutical use of substituted 1,2,4-triazoles |
| WO2004089416A2 (en) | 2003-04-11 | 2004-10-21 | Novo Nordisk A/S | Combination of an 11beta-hydroxysteroid dehydrogenase type 1 inhibitor and an antihypertensive agent |
| WO2004103991A1 (en) | 2003-05-20 | 2004-12-02 | 'chemical Diversity Research Institute', Ltd. | 2-substituted piperidines, focused library and a pharmaceutical compound |
| WO2005020885A2 (en) | 2003-05-21 | 2005-03-10 | Isis Pharmaceuticals, Inc. | Compositions and methods for the treatment of severe acute respiratory syndrome (sars) |
| US7820837B2 (en) | 2003-05-30 | 2010-10-26 | Takeda Pharmaceutical Company Limited | Condensed ring compound |
| US7405295B2 (en) | 2003-06-04 | 2008-07-29 | Cgi Pharmaceuticals, Inc. | Certain imidazo[1,2-a]pyrazin-8-ylamines and method of inhibition of Bruton's tyrosine kinase by such compounds |
| US7393848B2 (en) | 2003-06-30 | 2008-07-01 | Cgi Pharmaceuticals, Inc. | Certain heterocyclic substituted imidazo[1,2-A]pyrazin-8-ylamines and methods of inhibition of Bruton's tyrosine kinase by such compounds |
| KR20060056944A (ko) | 2003-07-14 | 2006-05-25 | 아레나 파마슈티칼스, 인크. | 대사 조절제로서 융합된 아릴 및 헤테로아릴 유도체 및이에 관련된 장애의 예방 또는 치료 |
| WO2005019220A2 (en) | 2003-08-11 | 2005-03-03 | Cellular Genomics Inc. | Substituted imidazo[1,2-a]pyrazines as modulators of kinase activity |
| KR100553752B1 (ko) | 2003-10-13 | 2006-02-20 | 삼성에스디아이 주식회사 | 이미다졸 고리 함유 화합물 및 이를 이용한 유기 전계발광 소자 |
| US7723324B2 (en) | 2003-10-28 | 2010-05-25 | Sepracor, Inc. | Imidazo[1,2-A]pyridine anxiolytics |
| WO2005047290A2 (en) | 2003-11-11 | 2005-05-26 | Cellular Genomics Inc. | Imidazo[1,2-a] pyrazin-8-ylamines as kinase inhibitors |
| CA2555263A1 (en) | 2004-02-12 | 2005-09-01 | Neurogen Corporation | Imidazo-pyridazines, triazolo-pyridazines and related benzodiazepine receptor ligands |
| US7306631B2 (en) | 2004-03-30 | 2007-12-11 | The Procter & Gamble Company | Keratin dyeing compounds, keratin dyeing compositions containing them, and use thereof |
| JP2005343889A (ja) | 2004-05-06 | 2005-12-15 | Taisho Pharmaceut Co Ltd | イミダゾピリジン誘導体 |
| WO2005120513A1 (en) | 2004-06-09 | 2005-12-22 | Oncalis Ag | Protein kinase inhibitors |
| GB0413605D0 (en) | 2004-06-17 | 2004-07-21 | Addex Pharmaceuticals Sa | Novel compounds |
| CA2577947A1 (en) | 2004-08-31 | 2006-03-09 | Banyu Pharmaceutical Co., Ltd. | Novel substituted imidazole derivative |
| AU2005295734A1 (en) | 2004-10-15 | 2006-04-27 | Biogen Idec Ma Inc. | Methods of treating vascular injuries |
| RU2007119637A (ru) | 2004-10-28 | 2008-12-10 | Айрм Ллк (Bm) | Соединения и композиции в качестве модуляторов hedgehog-пути |
| WO2006049339A1 (ja) | 2004-11-08 | 2006-05-11 | Banyu Pharmaceutical Co., Ltd. | 新規縮環イミダゾール誘導体 |
| JP2008519843A (ja) | 2004-11-10 | 2008-06-12 | シージーアイ ファーマスーティカル インコーポレーテッド | 特定のイミダゾ[1,2−a]ビラジン−8−イラミンズ、その生成方法及びそれに関する使用方法 |
| WO2006076131A2 (en) | 2004-12-17 | 2006-07-20 | Smithkline Beecham Corporation | Chemical compounds |
| JPWO2006070943A1 (ja) | 2004-12-28 | 2008-06-12 | 武田薬品工業株式会社 | 縮合イミダゾール化合物およびその用途 |
| US7998974B2 (en) | 2005-03-03 | 2011-08-16 | Sirtris Pharmaceuticals, Inc. | Fused heterocyclic compounds and their use as sirtuin modulators |
| US7666880B2 (en) | 2005-03-21 | 2010-02-23 | S*Bio Pte Ltd. | Imidazo[1,2-A]pyridine derivatives: preparation and pharmaceutical applications |
| CN101142217B (zh) | 2005-03-21 | 2010-12-08 | 伊莱利利公司 | 咪唑并哒嗪化合物 |
| JP2008536817A (ja) | 2005-03-24 | 2008-09-11 | グラクソ グループ リミテッド | 胃腸疾患の処置用医薬として有用なイミダゾ(1,2−a)ピリジン誘導体 |
| US7557103B2 (en) | 2005-04-05 | 2009-07-07 | Eli Lilly And Company | Imidazopyridazine compounds |
| US7572807B2 (en) | 2005-06-09 | 2009-08-11 | Bristol-Myers Squibb Company | Heteroaryl 11-beta-hydroxysteroid dehydrogenase type I inhibitors |
| GB0513423D0 (en) | 2005-06-30 | 2005-08-03 | Glaxo Group Ltd | Novel compounds |
| EP2246346B1 (en) | 2005-07-11 | 2012-10-24 | Novartis AG | Indolylmaleimide derivatives as protein kinase inhibitors |
| US20100216798A1 (en) | 2005-07-29 | 2010-08-26 | Astellas Pharma Inc | Fused heterocycles as lck inhibitors |
| US20070185063A1 (en) | 2005-08-23 | 2007-08-09 | Idenix Pharmaceuticals, Inc. | Seven-membered ring nucleosides |
| US20070049591A1 (en) | 2005-08-25 | 2007-03-01 | Kalypsys, Inc. | Inhibitors of MAPK/Erk Kinase |
| EP1928237A4 (en) | 2005-09-02 | 2011-03-09 | Abbott Lab | NEW HETEROCYCLES BASED ON IMIDAZO |
| US20070078136A1 (en) | 2005-09-22 | 2007-04-05 | Bristol-Myers Squibb Company | Fused heterocyclic compounds useful as kinase modulators |
| US7723336B2 (en) | 2005-09-22 | 2010-05-25 | Bristol-Myers Squibb Company | Fused heterocyclic compounds useful as kinase modulators |
| ATE463495T1 (de) | 2005-09-27 | 2010-04-15 | Hoffmann La Roche | Oxadiazolylpyrazolopyrimidine als mglur2- antagonisten |
| AU2006296386A1 (en) | 2005-09-30 | 2007-04-05 | Astrazeneca Ab | Imidazo [1,2-a] pyridine having anti-cell-proliferation activity |
| JO2769B1 (en) | 2005-10-26 | 2014-03-15 | جانسين فارماسوتيكا ان. في | Rapid decomposition of physiologically antagonistic agents of the 2-dopamine receptor |
| EP1945216A1 (en) | 2005-11-10 | 2008-07-23 | Schering Corporation | Methods for inhibiting protein kinases |
| EP1945644A2 (en) | 2005-11-10 | 2008-07-23 | Schering Corporation | Imidazopyrazines as protein kinase inhibitors |
| WO2007078815A2 (en) | 2005-12-16 | 2007-07-12 | Cytokinetics, Inc. | Certain chemical entities, compositions, and methods |
| EP2474546A1 (en) | 2006-01-23 | 2012-07-11 | Vertex Pharmaceuticals Inc. | Thiophene-carboxamides useful as inhibitors of protein kinases |
| WO2007087548A2 (en) | 2006-01-25 | 2007-08-02 | Smithkline Beecham Corporation | Chemical compounds |
| JP2009528388A (ja) | 2006-03-02 | 2009-08-06 | スミスクライン・ビーチャム・コーポレイション | Pi3キナーゼ阻害物質として用いられるチアゾロン |
| JP2009539840A (ja) | 2006-06-06 | 2009-11-19 | シェーリング コーポレイション | プロテインキナーゼ阻害剤としてのイミダゾピラジン |
| US20090175852A1 (en) | 2006-06-06 | 2009-07-09 | Schering Corporation | Imidazopyrazines as protein kinase inhibitors |
| ITVA20060041A1 (it) | 2006-07-05 | 2008-01-06 | Dialectica Srl | Uso di composti derivati amminotiazolici, di loro composizioni farmaceutiche, nel trattamento di malattie caratterizzate dalla anormale repressione della trascrizione genica, particolarmente il morbo di huntington |
| BRPI0713187A2 (pt) | 2006-07-20 | 2012-10-16 | Mehmet Kahraman | método de inibir rho-quinase, método de tratamento de doença mediada por rho-quinase, composto e composição farmacêutica |
| EP2046333A4 (en) | 2006-07-24 | 2010-09-15 | Glaxosmithkline Llc | THIOZOLIDINEDIONE DERIVATIVES AS INHIBITORS OF P13-KINASE |
| US7563797B2 (en) | 2006-08-28 | 2009-07-21 | Forest Laboratories Holding Limited | Substituted imidazo(1,2-A)pyrimidines and imidazo(1,2-A) pyridines as cannabinoid receptor ligands |
| US8268809B2 (en) | 2006-09-05 | 2012-09-18 | Emory University | Kinase inhibitors for preventing or treating pathogen infection and method of use thereof |
| WO2008030795A2 (en) | 2006-09-05 | 2008-03-13 | Boards Of Regents, The University Of Texas System | Compositions and methods for inhibition of tyrosine kinases |
| CN101594909A (zh) | 2006-09-07 | 2009-12-02 | 比奥根艾迪克Ma公司 | 用于治疗炎性病症、细胞增殖性失调、免疫失调的irak调节剂 |
| CN101553224A (zh) | 2006-10-06 | 2009-10-07 | 艾博特公司 | 新型咪唑并噻唑和咪唑并唑 |
| WO2008053285A1 (en) | 2006-10-30 | 2008-05-08 | Draximage Limited | Methods for preparing 2-methoxyisobutylisonitrile and tetrakis(2-methoxyisobutylisonitrile)copper(i) tetrafluoroborate |
| WO2008057402A2 (en) | 2006-11-02 | 2008-05-15 | Cytovia, Inc. | N-aryl-isoxazolopyrimidin-4-amines and related compounds as activators of caspases and inducers of apoptosis and the use thereof |
| PE20080931A1 (es) | 2006-11-08 | 2008-07-19 | Schering Corp | Imidazopirazinas como inhibidores de proteina quinasa |
| CA2670044A1 (en) | 2006-11-20 | 2008-05-29 | Alantos Pharmaceuticals Holding, Inc. | Heterobicyclic matrix metalloprotease inhibitors |
| US7622584B2 (en) | 2006-11-24 | 2009-11-24 | Samsung Mobile Display Co., Ltd. | Imidazopyridine-based compound and organic light emitting diode including organic layer comprising the imidazopyridine-based compound |
| UA96964C2 (ru) | 2006-12-04 | 2011-12-26 | Астразенека Аб | Соединения полициклической мочевины с антибактериальными свойствами |
| US7977336B2 (en) | 2006-12-28 | 2011-07-12 | Banyu Pharmaceutical Co. Ltd | Aminopyrimidine derivatives as PLK1 inhibitors |
| WO2008088692A2 (en) | 2007-01-12 | 2008-07-24 | Merck & Co., Inc. | Spirochromanon derivatives |
| US20080242862A1 (en) | 2007-03-27 | 2008-10-02 | Calderwood David J | Novel imidazo based heterocycles |
| JP2010522765A (ja) | 2007-03-28 | 2010-07-08 | アレイ バイオファーマ、インコーポレイテッド | 受容体チロシンキナーゼとしてのイミダゾ[1,2−a]ピリジン化合物 |
| UA101611C2 (ru) | 2007-04-03 | 2013-04-25 | Аррей Байофарма Инк. | СОЕДИНЕНИЯ ИМИДАЗО[1,2-а]ПИРИДИНА КАК ИНГИБИТОРЫ ТИРОЗИНКИНАЗЫ РЕЦЕПТОРОВ |
| CN103204852A (zh) | 2007-04-10 | 2013-07-17 | H.隆德贝克有限公司 | 作为p2x7拮抗剂的杂芳基酰胺类似物 |
| WO2008133192A1 (ja) | 2007-04-19 | 2008-11-06 | Takeda Pharmaceutical Company Limited | 縮合イミダゾール化合物およびその用途 |
| WO2008134553A1 (en) | 2007-04-26 | 2008-11-06 | Xenon Pharmaceuticals Inc. | Methods of using bicyclic compounds in treating sodium channel-mediated diseases |
| EP2155753A1 (en) | 2007-05-09 | 2010-02-24 | Novartis Ag | Substituted imidazopyridazines as pi3k lipid kinase inhibitors |
| DK2155758T3 (da) | 2007-05-10 | 2012-11-05 | Biocryst Pharm Inc | Tetrahydrofuro[3,4-d]dioxolanforbindelser til anvendelse i behandlingen af virusinfektioner og cancer |
| BRPI0811898A2 (pt) | 2007-06-01 | 2019-09-24 | Glaxosmithkline Llc | composto, composição farmacêutica, métodos para tratar um neoplasma suscetível e um câncer em um mamífero, processo para preparar um composto, e, uso de um composto. |
| PE20090365A1 (es) | 2007-06-14 | 2009-04-04 | Schering Corp | Imidazopirazinas como inhibidores de proteina quinasa |
| KR101030007B1 (ko) | 2007-06-15 | 2011-04-20 | 삼성모바일디스플레이주식회사 | 헤테로방향환 함유 화합물, 이의 제조 방법 및 이를 이용한유기 발광 소자 |
| WO2009002534A1 (en) | 2007-06-26 | 2008-12-31 | Gilead Colorado, Inc. | Imidazopyridinyl thiazolyl histone deacetylase inhibitors |
| WO2009005675A1 (en) | 2007-06-28 | 2009-01-08 | Abbott Laboratories | Novel triazolopyridazines |
| FR2918061B1 (fr) | 2007-06-28 | 2010-10-22 | Sanofi Aventis | Derives de 6-cycloamino-3-(pyridin-4-yl)imidazo°1,2-b!- pyridazine,leur preparation et leur application en therapeutique. |
| FR2918986B1 (fr) | 2007-07-19 | 2009-09-04 | Sanofi Aventis Sa | Derives de 6-cycloamino-3-(pyridazin-4-yl)imidazo[1,2-b]- pyridazine, leur preparation et leur application en therapeutique |
| EP2185512B1 (en) | 2007-07-27 | 2010-12-29 | Actelion Pharmaceuticals Ltd. | Trans-3-aza-bicyclo[3.1.0]hexane derivatives |
| KR20100042287A (ko) | 2007-07-31 | 2010-04-23 | 쉐링 코포레이션 | 항암요법으로서의 항-유사분열제 및 아우로라 키나제 억제제 조합물 |
| CN101842098A (zh) | 2007-08-10 | 2010-09-22 | 基因实验室技术有限公司 | 用于治疗病毒感染的含氮的二环化学实体 |
| CA2695251C (en) | 2007-08-14 | 2016-06-21 | Bayer Schering Pharma Aktiengesellschaft | Fused imidazoles for cancer treatment |
| ES2421237T7 (es) | 2007-08-15 | 2013-09-30 | Arena Pharmaceuticals, Inc. | Derivados de imidazo[1,2-a]piridin como moduladores del receptor serotoninérgico 5ht2a en el tratamiento de trastornos relacionados con el mismo |
| GB0716292D0 (en) | 2007-08-21 | 2007-09-26 | Biofocus Dpi Ltd | Imidazopyrazine compounds |
| US20110046127A1 (en) | 2007-11-08 | 2011-02-24 | Paolo Pevarello | Imidazopyridazines for Use as Protein Kinase Inhibitors |
| CA2704645A1 (en) | 2007-11-09 | 2009-05-14 | The Salk Institute For Biological Studies | Non-nucleoside reverse transcriptase inhibitors |
| EP2225248A1 (en) * | 2007-11-30 | 2010-09-08 | Wyeth LLC | Aryl and heteroaryl fused imidazo[1,5-a]pyrazines as inhibitors of phosphodiesterase 10 |
| EP2229390B1 (en) | 2007-12-14 | 2014-04-09 | F. Hoffmann-La Roche AG | Novel imidazoý1,2-a¨pyridine and imidazoý1,2-b¨pyridazine derivatives |
| WO2009086123A1 (en) | 2007-12-21 | 2009-07-09 | Wyeth | Imidazo [1,2-a] pyridine compounds |
| CA2710458A1 (en) | 2007-12-21 | 2009-07-09 | Wyeth Llc | Imidazo [1,2-b] pyridazine compounds as modulators of liver x receptors |
| JP5355421B2 (ja) | 2007-12-21 | 2013-11-27 | 出光興産株式会社 | 有機エレクトロルミネッセンス素子 |
| FR2926556B1 (fr) | 2008-01-22 | 2010-02-19 | Sanofi Aventis | Derives de carboxamides n-azabicycliques, leur preparation et leur application en therapeutique |
| CA2710929A1 (en) | 2008-01-28 | 2009-08-06 | Schering Corporation | Imidazopyrazines as protein kinase inhibitors |
| US8329697B2 (en) | 2008-02-26 | 2012-12-11 | Merck Sharp & Dohme Corp. | Imidizo[1,2-A]pyrazines useful as AHCY hydrolase inhibitors |
| AU2009226024B2 (en) | 2008-03-20 | 2012-07-12 | Amgen Inc. | Aurora kinase modulators and method of use |
| AU2009233711B2 (en) | 2008-04-09 | 2015-02-12 | Infinity Pharmaceuticals, Inc | Inhibitors of fatty acid amide hydrolase |
| DE102008017853A1 (de) | 2008-04-09 | 2009-10-15 | Merck Patent Gmbh | Thienopyrimidine |
| PL2280973T3 (pl) | 2008-04-23 | 2013-05-31 | Gilead Sciences Inc | Analogi karba-nukleozydowe do leczenia przeciwwirusowego |
| WO2010036407A2 (en) | 2008-05-15 | 2010-04-01 | Biocryst Pharmaceuticals, Inc. | Antiviral nucleoside analogs |
| AU2009249186B2 (en) | 2008-05-19 | 2014-05-22 | Sunovion Pharmaceuticals Inc. | Imidazo [1, 2-a] pyridine compounds as GABA-A receptor modulators |
| CN102112475A (zh) | 2008-05-29 | 2011-06-29 | 西特里斯药业公司 | 作为沉默调节蛋白调节剂的咪唑并吡啶和相关的类似物 |
| AR072008A1 (es) | 2008-06-13 | 2010-07-28 | Merck & Co Inc | Compuestos heterobiciclicos como agentes de inhibicion de quinasa p38 |
| EP2306836B1 (en) | 2008-07-01 | 2016-09-07 | PTC Therapeutics, Inc. | Bmi-1 protein expression modulators |
| EP2303881A2 (en) | 2008-07-14 | 2011-04-06 | Gilead Sciences, Inc. | Fused heterocyclyc inhibitors of histone deacetylase and/or cyclin-dependent kinases |
| WO2010011837A1 (en) | 2008-07-24 | 2010-01-28 | Bristol-Myers Squibb Company | Fused heterocyclic compounds useful as kinase modulators |
| JP5576370B2 (ja) | 2008-08-06 | 2014-08-20 | ファイザー・インク | Chk−1阻害剤としての6置換2−ヘテロシクリルアミノピラジン化合物 |
| FR2934994B1 (fr) | 2008-08-12 | 2010-09-17 | Sanofi Aventis | Derives de 2-alkyl-6cycloamino-3-(pyridin-4-yl)imidaz°1,2-b! pyridazine, leur preparation et leur application en therapeutique |
| US8198449B2 (en) | 2008-09-11 | 2012-06-12 | Bristol-Myers Squibb Company | Compounds for the treatment of hepatitis C |
| WO2010033906A2 (en) | 2008-09-19 | 2010-03-25 | President And Fellows Of Harvard College | Efficient induction of pluripotent stem cells using small molecule compounds |
| WO2010048149A2 (en) | 2008-10-20 | 2010-04-29 | Kalypsys, Inc. | Heterocyclic modulators of gpr119 for treatment of disease |
| JP5416944B2 (ja) | 2008-10-23 | 2014-02-12 | ユー・ディー・シー アイルランド リミテッド | 有機電界発光素子 |
| WO2010054253A1 (en) | 2008-11-07 | 2010-05-14 | Biotie Therapies Gmbh | Triazine derivatives as inhibitors of phosphodiesterases |
| WO2010059838A2 (en) | 2008-11-20 | 2010-05-27 | Decode Genetics Ehf | Pde4 inhibitors selective for the long form of pde4 for treating inflammation and avoiding side effects |
| WO2010059836A1 (en) | 2008-11-20 | 2010-05-27 | Decode Genetics Ehf | Substituted aza-bridged bicyclics for cardiovascular and cns disease |
| GB0822981D0 (en) | 2008-12-17 | 2009-01-21 | Summit Corp Plc | Compounds for treatment of duchenne muscular dystrophy |
| CA2746307C (en) * | 2008-12-17 | 2013-11-19 | Amgen Inc. | Aminopyridine and carboxypyridine compounds as phosphodiesterase 10 inhibitors |
| JP5210187B2 (ja) | 2009-01-22 | 2013-06-12 | ユー・ディー・シー アイルランド リミテッド | 有機電界発光素子 |
| EP2210891A1 (en) | 2009-01-26 | 2010-07-28 | Domain Therapeutics | New adenosine receptor ligands and uses thereof |
| WO2010088518A2 (en) | 2009-01-31 | 2010-08-05 | Kalypsys, Inc. | Heterocyclic modulators of gpr119 for treatment of disease |
| WO2010097367A1 (en) | 2009-02-24 | 2010-09-02 | Janssen Pharmaceutica Nv | Radiolabelled pde10 ligands |
| US8367222B2 (en) | 2009-02-27 | 2013-02-05 | Idemitsu Kosan Co., Ltd. | Organic electroluminescent device |
| AU2010219598A1 (en) * | 2009-03-05 | 2011-09-22 | Astellas Pharma Inc. | Quinoxaline compounds |
| CA2755285C (en) | 2009-03-20 | 2014-02-11 | Yunxin Y. Bo | Inhibitors of pi3 kinase |
| WO2010110277A1 (ja) | 2009-03-24 | 2010-09-30 | 出光興産株式会社 | 有機エレクトロルミネッセンス素子 |
| NZ596185A (en) | 2009-04-16 | 2013-01-25 | Ct Nac Investigaciones Oncologicas Cnio | Imidazopyrazines for use as kinase inhibitors |
| TW201111383A (en) * | 2009-05-29 | 2011-04-01 | Wyeth Llc | Substituted imidazo[1,5-a]quinoxalines as inhibitors of phosphodiesterase 10 |
| TW201107329A (en) | 2009-07-30 | 2011-03-01 | Oncotherapy Science Inc | Fused imidazole derivative having ttk inhibitory action |
| WO2011021520A1 (ja) | 2009-08-19 | 2011-02-24 | 出光興産株式会社 | 芳香族アミン誘導体及びそれを用いた有機エレクトロルミネッセンス素子 |
| PH12012500778A1 (en) | 2009-10-30 | 2012-11-26 | Janssen Pharmaceutica Nv | IMIDAZO[1,2-b]PYRIDAZINE DERIVATIVES AND THEIR USE AS PDE10 INHIBITORS |
| KR20120066076A (ko) | 2009-11-16 | 2012-06-21 | 이데미쓰 고산 가부시키가이샤 | 방향족 아민 유도체 및 그것을 이용한 유기 전기발광 소자 |
| CA2787714C (en) | 2010-01-22 | 2019-04-09 | Joaquin Pastor Fernandez | Inhibitors of pi3 kinase |
| AR080754A1 (es) | 2010-03-09 | 2012-05-09 | Janssen Pharmaceutica Nv | Derivados de imidazo (1,2-a) pirazina y su uso como inhibidores de pde10 |
| US9540379B2 (en) | 2011-01-31 | 2017-01-10 | Boehringer Ingelheim International Gmbh | (1,2,4)triazolo[4,3-A]quinoxaline derivatives as inhibitors of phosphodiesterases |
| AU2012247564B2 (en) | 2011-04-28 | 2016-05-26 | Janssen Pharmaceutica Nv | Salt of an inhibitor of phosphodiesterase 10 enzyme |
| JP6115962B2 (ja) | 2011-06-27 | 2017-04-19 | ヤンセン ファーマシューティカ エヌ.ベー. | 1−アリール−4−メチル−[1,2,4]トリアゾロ[4,3−a]キノキサリン誘導体 |
| US9056863B2 (en) | 2011-09-09 | 2015-06-16 | H. Lundbeck A/S | Substituted 2,3,5,9,9B-pentaazacyclopenta[a]naphthalenes and uses thereof |
| WO2013034755A1 (en) | 2011-09-09 | 2013-03-14 | H. Lundbeck A/S | Triazolopyrazine derivatives and their use for treating neurological and psychiatric disorders |
| AU2013289284B2 (en) | 2012-07-09 | 2017-03-30 | Janssen Pharmaceutica Nv | Inhibitors of phosphodiesterase 10 enzyme |
-
2012
- 2012-06-26 JP JP2014517667A patent/JP6115962B2/ja not_active Expired - Fee Related
- 2012-06-26 ES ES12729637.4T patent/ES2575092T3/es active Active
- 2012-06-26 BR BR112013033375-8A patent/BR112013033375B1/pt not_active IP Right Cessation
- 2012-06-26 CN CN201280031255.3A patent/CN103619846B/zh not_active Expired - Fee Related
- 2012-06-26 AU AU2012277912A patent/AU2012277912B2/en not_active Ceased
- 2012-06-26 MX MX2013015201A patent/MX344600B/es active IP Right Grant
- 2012-06-26 EA EA201490165A patent/EA027418B1/ru not_active IP Right Cessation
- 2012-06-26 EP EP12729637.4A patent/EP2723744B1/en active Active
- 2012-06-26 US US14/128,835 patent/US10604523B2/en not_active Expired - Fee Related
- 2012-06-26 CA CA2838645A patent/CA2838645C/en active Active
- 2012-06-26 WO PCT/EP2012/062381 patent/WO2013000924A1/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP4754068B2 (ja) | δ−オピオイドレセプターに結合する4−[アリール(ピペリジン−4−イル)]アミノベンズアミド類 | |
| AU2002340184B2 (en) | Imidazo (4,3-E)-1,2,4-triazolo(1,5-C) pyrimidines as adenosine A2A receptor antagonists | |
| EP2370437B1 (en) | Bicyclic pyrazole and isoxazole derivatives as antitumor and antineurodegenerative agents | |
| JP4284182B2 (ja) | アデノシンA2aレセプターアンタゴニスト | |
| RU2459806C2 (ru) | Замещенные гетероарильные производные | |
| ES2442926T3 (es) | Derivados de ciclopropilamida `978 | |
| JP6115962B2 (ja) | 1−アリール−4−メチル−[1,2,4]トリアゾロ[4,3−a]キノキサリン誘導体 | |
| CN101686952A (zh) | 新型钙离子通道调节剂 | |
| US10294227B2 (en) | Compounds | |
| JP2018500342A (ja) | トリアゾロピリミジン化合物およびその使用 | |
| JP2006510716A5 (cg-RX-API-DMAC7.html) | ||
| EA015034B1 (ru) | 2-анилин-4-арилзамещенные тиазольные производные | |
| JP6082457B2 (ja) | Gpr17受容体調節因子 | |
| JP2016520118A (ja) | Bet阻害剤としてのピラゾロ−ピロリジン−4−オン誘導体および疾患の処置におけるその使用 | |
| CA3236339A1 (en) | Indolizine compounds for the treatment of mental disorders or mental enhancement | |
| EA037481B1 (ru) | Производные 3-((гетеро-)арил)алкил-8-амино-2-оксо-1,3-диазаспиро[4.5]декана | |
| TW201321353A (zh) | 胺基甲酸酯/尿素衍生物 | |
| JP2018509442A (ja) | Fgfr4阻害剤としてのホルミル化n−複素環式誘導体 | |
| JP2008501758A (ja) | ピロロピリジン誘導体 | |
| SK83098A3 (en) | 1-(1,2-disubstituted piperidinyl)-4-(fused imidazole)-piperidine derivatives | |
| Sippy et al. | Preparation and characterization of N-(3-pyridinyl) spirocyclic diamines as ligands for nicotinic acetylcholine receptors | |
| SK82998A3 (en) | Substituted piperidines as tachykinin antagonists | |
| McKinnell et al. | Discovery of TD-8954, a clinical stage 5-HT4 receptor agonist with gastrointestinal prokinetic properties | |
| JP2008546711A (ja) | Cns障害の処置のためのヘキサヒドロ−ピロロ−イソキノリン化合物 | |
| US9340530B2 (en) | Preparation and use of bicyclic himbacine derivatives as PAR-1 receptor antagonists |